CHARACTERISTICS OF METABOLISM AND WORKING OUT THE METHODS OF DETERMINATION OF SYNTHETIC CANNABINOID THJ-2201 IN THE URINE OF LABORATORY ANIMALS


Cite item

Full Text

Abstract

The proposed article touches upon the study of metabolism of new synthetic cannabinoids. In the work the data on synthetic cannabinoid 3-(Naftalin-1-yloxomethyl)-1-(5-fluoropentyl)-1H-indazole (THJ-2201), as well as the products of its metabolism in the laboratory rats of the Wistar line are given, i. e. Mass spectra and chromatograms of the native substance (THJ-2201) obtained by high-performance liquid chromatography with mass-selective detection (HPLC-MS) and gas chromatography with mass-selective detection (GC-MS) are given. The paper presents a complex technique for qualitative determination of cannabimimetics THJ-2201 and methods for obtaining a metabolic profile model for the test substance that can be useful for the tasks of qualitative detection and detection of new psychoactive substances in biological objects for the purposes of forensic analysis.The aim of this work was to develop methods for determination of the test substance (THJ-2201) and its metabolites in the urine of laboratory animals, as well as the study of the metabolic characteristics of synthetic cannabinoids on the whole.Materials and methods. The following equipment was used for the experiment: a liquid chromatograph from the firm “Shimadzu LCMC-8050” in combination with a mass-selective detector. The detector type is a triple quadrupole with a double ionization source (chemical ionization at atmospheric pressure and electrospray). The separation of the substances occurred in a chromatographic column (the material is stainless steel, the characteristics are: 150 * 3.0 mm, Luna 3uC18 (2), 100A). The Sorbent is reversed-phase. The investigations were carried out on Agilent 7890A gas chromatograph with Agilent 5975C mass spectrometer and a 103 polar HP-5ms column of 28 m × 0.25 mm. The animals were mature male white laboratory rats of the Wistar line, aged 4–6 months, weighing 190-230 grams.Results and discussion. As a result of the studies, a comprehensive methodology for determining the synthetic cannabimimetics of THJ-2201 and its metabolites in the urine of laboratory animals was developed, chromatograms and mass spectra of the metabolic profile of animals were obtained by HPLC-MS and GC-MS methods, and the similarity of the metabolic profiles of the studied substances in humans and animals was determined.Conclusion. The conclusions were made about the suitability of the proposed complex analysis methodology under the given laboratory conditions and the significant degree of interspecific similarity of human metabolic profiles and laboratory rats’ for substances chemically close to the studied.

Full Text

ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryциɬиɪоɜɚнияМɚлкоɜɚɏȺɊȺКɌȿɊИɋɌИКȺМȿɌȺȻОЛИЗМȺɊȺЗɊȺȻОɌКȺМȿɌОȾИКОПɊȿȾȿЛȿНИЯɋИНɌȿɌИЧȿɋКОȽО THJ-2201МОЧȿЛȺȻОɊȺɌОɊНЫɏɎɚɪмɚцияɮɚɪмɚколоɝияМɚлкоɜɚFor citation:Apushkin D. Yu., Malkova T.L. CHARACTERISTICS OF METABOLISM AND WORKING OUT THE METHODS OF DETERMINATION OF SYNTHETIC CANNABINOID THJ-2201 IN THE URINE OF LABORATORY ANIMALS.Pharmacy & Pharmacology. ɍȾКˈʤˀʤК˃ʫˀʰˁ˃ʰКʤʺʫ˃ʤʥОЛʰʯʺʤˀʤʯˀʤʥО˃Кʤʺʫ˃ОʪʰКОʿˀʫʪʫЛʫʻʰЯˁʰʻ˃ʫ˃ʰЧʫˁКОʧО THJЛʤʥОˀʤ˃ОˀʻˏˈʮʰʦО˃ʻˏˈМɚлкоɜɚɎȽȻОɍПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияМинзɞɪɚɜɚɊоɫɫииɊоɫɫияПɟɪмьПолɟɜɚяпɪɟɞложɟннойɫɬɚɬьɟɜопɪоɫыизɭчɟниямɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛиноɪɚɛоɬɟпɪɟɞɫɬɚɜлɟныɫинɬɟɬичɟɫкомкɚннɚɛиноиɞɟ 3-(Нɚɮɬɚлинилокɫомɟɬилинɞɚзол (THJ-2201), ɬɚкжɟпɪоɞɭкɬɚɯмɟɬɚɛолизмɚоɪɝɚнизмɟлɚɛоɪɚɬоɪныɯɫɬокɚ Wistar, пɪиɜɟɞɟныɫпɟкɬɪыɯɪомɚɬоɝɪɚммыɜɟщɟɫɬɜɚ (THJ-2201), полɭчɟнныɟпомощьюмɟɬоɞоɜɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɫɟлɟкɬиɜнойȼЭЖɏɝɚзоɜойɯɪомɚɬоɝɪɚɮииɫɟлɟкɬиɜнойɞɟɬɟкциɟйɪɚɛоɬɟпɪɟɞɫɬɚɜлɟнɚкомплɟкɫнɚямɟɬоɞикɚкɚчɟɫɬɜɟнноɝоопɪɟɞɟлɟниякɚннɚɛимимɟɬикɚ THJ-2201 мɟɬоɞикɚполɭчɟниямоɞɟлимɟɬɚɛоличɟɫкоɝоиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚкоɬоɪɚяможɟɬполɟзнойзɚɞɚччɟɫɬɜɟнноɝоопɪɟɞɟлɟнияоɛнɚɪɭжɟнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɛиолоɝичɟɫкиɯоɛъɟкɬɚɯцɟлɟйɫɭɞɟɛноɯимичɟɫкоɝоЦɟльюнɚɫɬоящɟйɪɚɛоɬыяɜлялɚɫьɪɚзɪɚɛоɬкɚмɟɬоɞикиопɪɟɞɟлɟнияиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚ (THJ-2201) мɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯɬɚкжɟиɫɫлɟɞоɜɚниɟоɫоɛɟнноɫɬɟймɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛиноиɞоɜцɟломМɚɬɟɪиɚлымɟɬоɞыпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚɛылоиɫпользоɜɚноɫлɟɞɭющɟɟоɛоɪɭɞоɜɚниɟжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮɮиɪмы ?Shimadzu комплɟкɫɟɫɟлɟкɬиɜнымɞɟɬɟкɬоɪомɌипɞɟɬɟкɬоɪɚкɜɚɞɪɭпольɞɜойнымиɫɬочникомɯимичɟɫкɚяɚɬмоɫɮɟɪномɞɚɜлɟнииэлɟкɬɪоɫпɪɟйɊɚзɞɟлɟниɟщɟɫɬɜпɪоиɫɯоɞилоɯɪомɚɬоɝɪɚɮичɟɫкойколонкɟ ? нɟɪжɚɜɟющɚяɫɬɚльɯɚɪɚкɬɟɪиɫɬики ? 150 ɋоɪɛɟнɬ ? оɛɪɚщённоИɫɫлɟɞоɜɚнияпɪоɜɟɞɟныɝɚзоɜомɯɪомɚɬо ?Agilent 7890A? ɫпɟкɬɪомɟɬɪом Agilent 5975C колонкой 103 нɟполяɪной HP-5ms 28 ? 0,25 Жиɜоɬныɟ ? полоɜозɪɟлыɟɫɚмцыɛɟлыɯлɚɛоɪɚɬоɪныɯɫɬокɚ Wistar, ɜозɪɚɫɬмɟɫяцɟɜмɚɫɫɚ 190Ɋɟзɭльɬɚɬыоɛɫɭжɞɟниɟɪɟзɭльɬɚɬɟпɪоɜɟɞённыɯиɫɫлɟɞоɜɚнийɛылɚɪɚзɪɚɛоɬɚнɚплɟкɫнɚямɟɬоɞикɚопɪɟɞɟлɟнияɫинɬɟɬичɟɫкоɝокɚннɚɛимиммɟɬикɚ THJ-2201 мɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯполɭчɟныɯɪомɚɬоɝɪɚммыɫпɟкɬɪымɟɬɚɛоличɟɫкоɝоɜоɬныɯпомощьюмɟɬоɞоɜȼЭЖɏɬɚкжɟɭɫɬɚноɜлɟнɚзнɚчиɬɟльнɚяɫɯожɟɫɬьмɟɬɚɛоличɟɫкиɯпɪоɮилɟйиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚчɟлоɜɟкɚжиɜоɬныɯЗɚключɟниɟɫɞɟлɚныɜыɜоɞыпɪиɝоɞноɫɬипɪɟɞложɟннойкомплɟкɫноймɟɬоɞикиɭɫлоɜияɯлɚɛоɪɚɬоɪиизнɚчиɬɟльноймɟжɜиɞоɜойɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯпɪоɮилɟйчɟлоɜɟкɚлɚɛоɪɚɬоɪнойɜɟщɟɫɬɜɯимичɟɫкиɛлизкиɯиɫɫлɟɞɭɟмымКлючɟɜыɟɫлоɜɚНɚɮɬɚлинилокɫомɟɬилɮɬоɪпɟнɬилинɞɚзоллɚɛоɪɚɬоɪныɟжиɜоɬныɟмɟɬɚɛолиɬыɫинɬɟɬичɟɫкиɟкɚннɚɛиноиɞыȼЭЖɏPharmacy & Pharmacology V. 5 N 4, 2017ȼɜɟɞɟниɟОɞнойɫɚмыɯоɫɬɪыɯпɪоɛлɟмɬоɪымиɫɬолкнɭлоɫьчɟлоɜɟчɟɫɬɜопоɫлɟɞниɟɞɜɚɞɟɫяɬкɚяɜляɟɬɫяпɪоɛлɟмɚнɟлɟɝɚльноɝоɫинɬɟзɚоɛоɪоɬɚпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɜɫɟмɭмиɪɭɜɟщɟɫɬɜкоɬоɪыɟиɫпользɭюɬɫяɪɟкɪɟɚционныɯɫожɚлɟниюɊоɫɫияɫɬɚлɚиɫключɟниɟмɬɟɪɪиɬоɪииɪɚɫпɪоɫɬɪɚнɟниɟɞɟɫяɬкиɜɟщɟɫɬɜиɫпользɭɟмыɯоɞɭɪмɚниɜɚниякɚжɞомɝоɫɭɞɚɪɫɬɜɟɫɜоɟмɭɛоɪюɬɫяэɬойпɪоɛлɟмойчɬоɫɜязɚнооɫоɛɟнноɫɬямизɚконоɞɚɬɟльɫɬɜɚɫɮɟɪɟоɛоɪоɬɚнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜȻɟзɭɫлоɜноɫɬɪɚнɟнɟзɚконнымоɛоɪоɬомоɞɭɪмɚниɜɚющиɯɜɟщɟɫɬɜɚкɬиɜноɜɟɞёɬɫяоɞнɚкозɚчɚɫɬɭюпɪоɯоɞиɬɞоɜольноɛольшойоɬɪɟзокмомɟнɬɚɪɭжɟнияноɜоɝоɫинɬɟɬичɟɫкоɝоɜɟщɟɫɬɜɚɟɝопɪɟɬɚɫинɬɟзɭпɪоизɜоɞɫɬɜɭчɟɪɟзɜключɟниɟконɬɪолиɪɭɟмыɯɜɟщɟɫɬɜȽɪɭппɚПɟɪмɫкойɝоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚцɟɜɬичɟɫкойɚкɚɞɟмииɛолɟɟ 7 ɜоɞиɬиɫɫлɟɞоɜɚнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɞɟйɫɬɜɭющɟɟɫɬɪɚнɟзɚконоɞɚɬɟльɫɬɜо [1, 2]. ɊоɫɫииоɛоɪоɬɚпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɜозможночɟɪɟзоɬнɟɫɟниɟɚнɚлоɝɚмнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜопɪɟɞɟлɟниɟкоɬоɪыɯпɪиɜɟɞɟноɎɟɞɟɪɚльномзɚконɟ 3- 08.01.1998 ЭɬɚɝɪɭппɚɜключɚɟɬɫɟɛяɚнɚлоɝинɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜзɚпɪɟщɟнныɟоɛоɪоɬɚɊоɫɫийɫкойɎɟɞɟɪɚцииɜɟщɟɫɬɜɚɫинɬɟɬичɟɫкоɝоɟɫɬɟɫɬɜɟнноɝопɪоиɫɯожɞɟнияɜключɟнныɟПɟɪɟчɟньнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜпɪɟкɭɪɫоɪоɜпоɞлɟжɚщиɯконɬɪолюɊоɫɫийɫкойɎɟɞɟɪɚцииɯимичɟɫкɚяɫɬɪɭкɬɭɪɚɫɜойɫɬɜɚкоɬоɪыɯɫɯоɞныɯимичɟɫкойɫɬɪɭкɬɭɫɜойɫɬɜɚминɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜɯоɬɪопныɯɜɟщɟɫɬɜпɫиɯоɚкɬиɜноɟкоɬоɜоɫпɪоизɜоɞяɬНɚкоплɟнныйпозɜолилɫɮоɪмиɪоɜɚɬьМɟɬоɞичɟɫкиɟɪɟкомɟнɞɚциииɫɫлɟɞоɜɚниюпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜпɪоцɟɞɭɪɟоɬнɟɫɟнияɚнɚлоɝɚмнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопɜɟщɟɫɬɜɊɟзɭльɬɚɬыиɫɫлɟɞоɜɚнийнɟоɞнокɪɚɬноɞоклɚɞыɜɚлиɫьконɮɟɪɟнцияɯɮоɪɭмɚɯCHARACTERISTICS OF METABOLISM AND WORKING OUT THE METHODS OF DETERMINATION OF SYNTHETIC CANNABINOID 2201 IN THE URINE OF LABORATORY ANIMALSD.Yu. Apushkin, T.L. Malkova Perm State Pharmaceutical Academy, The proposed article touches upon the study of metabolism of new synthetic cannabinoids. In the work the data uoropentyl)-1H-indazole (THJ-2201), as well as the prod-ucts of its metabolism in the laboratory rats of the Wistar line are given, i. e. Mass spectra and chromatograms of the native substance (THJ-2201) obtained by high-performance liquid chromatography with mass-selective detection (HPLC-MS) and gas chromatography with mass-selective detection (GC-MS) are given. The paper presents a complex technique for qualitative determination of cannabimimetics THJ-2201 and methods for obtaining a metabolic prosubstances in biological objects for the purposes of forensic analysis. equipment was used for the experiment: a liquid chromatograph from the tion with a mass-selective detector. The detector type is a triple quadrupole with a double ionization source (chemical ionization at atmospheric pressure and electrospray). The separation of the substances occurred in a chromatograph-ic column (the material is stainless steel, the characteristics are: 150 * 3.0 mm, Luna 3uC18 (2), 100A). The Sorbent is reversed-phase. The investigations were carried out on Agilent 7890A gas chromatograph with Agilent 5975C mass spectrometer and a 103 polar HP-5ms column of 28 m ? 0.25 mm. The animals were mature male white laboratory rats of the Wistar line, aged 4As a result of the studies, a comprehensive methodology for determining the synthetic cannabimimetics of THJ-2201 and its metabolites in the urine of laboratory animals was developed, chromatograms and mass spectra of the metabolic pro le of animals were obtained by HPLC-MS and GC-MS methods, and the similarity of the metabolic pro les of the studied substances in The conclusions were made about the suitability of the proposed cant degree of interspeci c simi-larity of human metabolic pro les and laboratory rats? for substances chemically close to the studied. uoropentyl)-1H-indazole, THJ-2201, laboratory animals, me-ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryнɚɯоɞилипоɞɞɟɪжкɭпɪɟɞɫɬɚɜиɬɟлɟйпɪɚɜооɯɪɚниэкɫпɟɪɬныɯɫлɭжɛɪɟкомɟнɞɚцииɪɚзɪɚɛоɬɚныоɛъɟкɬоɜиɫɫлɟɞоɜɚнияпɪɟɞɫɬɚɜляющиɯщɟɫɬɜɟнныɟɞокɚзɚɬɟльɫɬɜɚɫɭɛɫɬɚнцииɫмɟɫимɚɫɫыɜɟɪояɬноɫоɞɟɪжɚщиɟɚнɚлоɝинɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜɊɚзɪɚɛоɬɚнныйɚлɝоɪиɬмиɫɫлɟɞоɜɚнияɜключɚɟɬɯимичɟɫкɭюɮɚɪмɚколоɝичɟɫкɭюМɟɬоɞичɟɫкиɯɪɟкомɟнɞɚцияɯпоɞɪоɛноопиɫɚнопочɟмɭиɫпользɭɟɬɫяɬɚкойпоɞɯоɞОɞнɚкооɛъɟкɬɚмиэкɫпɟɪɬноɝоиɫɫлɟɞоɜɚнияпɪоɜоɞимоɝоɪɭжɟнияпɫиɯоɚкɜɟщɟɫɬɜɬолькоɜɟщɟɫɬɜɟнɞокɚзɚɬɟльɫɬɜɚнɟɛиолоɝичɟɫкоɝоɯɚɪɚкɬɟɪɚɛиолоɝичɟɫкиɟжиɞкоɫɬичɬонɚиɛолɟɟɜоɫɬɪɟɛоɜɚнопɪоɜɟɞɟниимɟɞицинɫкоɝооɫɜиɞɟɬɟльɫɬɜоɜɚнияɭпоɬɪɟɛляющиɯоɞɭɪмɚниɜɚющиɟɜɟщɟɫɬɜɚЧɬоɛыɭɫɬɚноɜиɬьɮɚкɬɭпоɬɪɟɛлɟниязɚпɪɟɜɟщɟɫɬɜɜпоɫлɟɞɫɬɜииопɪɟɞɟлиɬьконɫɬɪɭкɬɭɪɭиɫɫлɟɞɭɟмоɝопɫиɯоɚкɬиɜноɝоɜɟщɟɫɬɜɚпɪимɟняюɬɫяɯɪомɚɬоɝɪɚɮичɟɫкиɟмɟɬоɚнɚлизɚɛиолоɝичɟɫкиɯоɛъɟкɬоɜɬомȼЭЖɏɜыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚɮиямɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬиɪоɜɚниɟмɝɚзоɜɚяɯɪомɚɬоɝɪɚɮиямɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬиɪоɜɚниɟмoxicological ChemistryОɞнимɫɚмыɯпɪɟɞɫɬɚɜиɬɟлɟйɞɚнноɝоклɚɫɫɚпɫиɯоɬɪопныɯɜɟщɟɫɬɜяɜляɟɬɫя 3-(Нɚɮɬɚлинилокɫомɟɬилɮɬоɪинɞɚзолизɜɟɫɬноɟпоɞɬɪиɜиɚльнымнɚзɜɚниɟм THJ-2201 AM(N)-2201. ?ПɪɚɪоɞиɬɟиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚможноɫчиɬɚɬьɞɪɭɝоɟпɫиɯоɚкɬиɜноɟɜɟщɟɫɬɜоизɜɟɫɬноɟпоɞнɚзɜɚниɟмJWH-018 (IUPAC: (1-нɚɮɬоилинɞол)), оɬличиɟзɚключɚɟɬɫяинɞольноɝоинɞозольноɟ ɋɬɪɭкɬɭɪнɚяɮоɪмɭлɚиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚпɪɟɞɫɬɚɜлɟнɚɪиɫɭнкɟɊиɫɭнокɋɬɪɭкɬɭɪнɚяɮоɪмɭлɚилокɫомɟɬилɮɬоɪпɟнɬилинɞɚзолɚɫɜоимɮɚɪмɚколоɝичɟɫкимɫɜойɫɬɜɚмɞɚнноɟɜɟщɟɫɬɜояɜляɟɬɫяполнымɚɝониɫɬомцɟнɬɪɚльныɯпɟɪиɮɟɪичɟɫкиɯ CB2 ɪɟцɟпɬоɪоɜ [5]. Поɫлɟпɪиёмɚɜɟщɟɫɬɜɚнɚɛлюɞɚюɬɫяɫлɟɞɭющиɟэɮɮɟкɜыɪɚжɟннɚяɫɟɞɚцияпоɬɟɪяконɬɪолямɟлкойкɪɭпноймоɬоɪикиɝлɚɞкиɯɬɪɭɞноɫɬиɟнɬɚциɟйпɪоɫɬɪɚнɫɬɜɟɫнижɟниɟɚɪɬɟɪиɚльноɝоɞɚɜлɟнияɬошноɬɚнɚɪɭшɟнияɞɪɭɝиɟ [5]. Цɟлью ɞɚнноɝоиɫɫлɟɞоɜɚнияяɜляɟɬɫяɛоɬкɚмɟɬоɞикиопɪɟɞɟлɟнияиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚɟɝомɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯɜыяɜлɟниɟɯɚɪɚкɬɟɪныɯмɟɬɚɛолиɬоɜɭкɚзыɜɚɟɬɮɚкɬɭпоɬɪɟɛлɟниязɚпɪɟщённоɝоɜɟщɟɫɬɜɚкɪомɟɬоɝоизɭчɟниɟмɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛимимɟɬикоɜцɟломɬɚкжɟляɟɬɫяɪɚɛоɬыоɬноɫиɬɟльноɛыɫɬɪоɝоɜыполнɟниякɚчɟɫɬɜɟнноɝоɚнɚлизɚмɟɬɚɛоличɟɫкиɯɫинɬɟзиɪоɜɚнныɯпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜможноиɫпользоɜɚɬьмɟɬɚɛоличɟɫкиɟкɚмɟɪылɚɛоɪɚɬоɪжиɜоɬныɯ ȼ пɪɟɞложɟнномиɫɫлɟɞоɜɚнииɪɚɫɫмоɬɪɟниɟпɪɟɞɫɬɚɜлɟнынɟкоɬоɪыɟмɟɬоɞичɟɫкиɟɪɟкомɟнɞɚмɟɬоɞоɜȼЭЖɏкɚчɟɫɬɜɟнноɝоопɪɟɞɟлɟниямɟɬɚɛолиɬоɜноɜоɝоɫинɬɟɬичɟɫкоɝокɚннɚɛимимɟɬикɚ THJ-2201 ɛиолоɝичɟɫкойжиɞкоɫɬимочɟлɚɛоɪɚɬоɪныɯМɚɬɟɪиɚлымɟɬоɞыИɫɫлɟɞɭɟмоɟɜɟщɟɫɬɜоɜɟщɟɫɬɜɚпɪɟɞоɫɬɚɜлɟнпɪɚɜооɯɪɚниɬɟльМиниɫɬɟɪɫɬɜɚȼнɭɬɪɟнниɯȾɟлɊоɫɫийɫкойɎɟɞɟɪɚцииɛɚзɭɊɟɝионɚльноɝоɫлɟɞоɜɚɬɟльɫкоɝоЦɟнɬɪɚɎɚɪмɚɬɟɫɬɭɫɬɚноɜɯимичɟɫкойɫɬɪɭкɬɭɪыопɪɟɞɟлɟнияɯимичɟɫкойɛлизоɫɬиɜɟщɟɫɬɜɚмпоимɟноɜɚннымɋпиɫкɟ I нɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜɬɚкжɟɭɫɬɚноɜлɟнияɚнɚлоɝичноɫɬизɚпɪɟщённымɜɟщɟɫɬɜɚмЛɚɛоɪɚɬоɪныɟжиɜоɬныɟЭкɫпɟɪимɟнɬыпɪоɜɟɞɟныɛɟлыɯполоɜозɪɟлыɯɫɚмцɚɯɬоɪныɯɫɬокɚ Wistar ɜозɪɚɫɬɟмɟɫямɚɫɫой 180-250 ЖиɜоɬныɟɫоɞɟɪжɚлиɫьɬɟɪɪиɬоɪииɜиɜɚɪияɎȽȻОɍПȽɎȺМинзɞɪɚɜɚɊоɫɫииоɬɞɟльнойкомнɚɬɟɬɟмпɟɪɚɬɭɪɟɜозɞɭ 22?2 ?ɜлɚжноɫɬиɜозɞɭɯɚ 55?-65%. Ⱦиɟɬɚ ? ɫɬɚнɞɚɪɬнɚялɚɛоɪɚɬоɪныɯжиɜоɬныɯȽОɋɌɫоɝлɚɫнолɚɛоɪɚɬоɪнойпɪɚкɬикипɪоɜɟɞɟнииɞоклиничɟɫкиɯиɫɫлɟɞоɜɚнийȽОɋɌPharmacy & Pharmacology V. 5 N 4, 2017ɋɯɟмɚэкɫпɟɪимɟнɬɚполɭчɟнияконɬɪольпоɫɬэкɫпозиционнойɛиожиɞкоɫɬиоɞноɝоɬоɝожиɜоɬноɝочɬонɟоɛɯоɞимоɫопоɫɬɚɜлɟɪɟзɭльɬɚɬоɜплɚниɪоɜɚнииэкɫпɟɪимɟнɬɚпользоɜɚлɚɫьɫлɟɞɭющɚяɫɯɟмɚɪɚɫɫɚɞкиɜоɬноɟпомɟщɚлоɫьмɟɬɚɛоличɟɫкɭюкɚмɟɪɭɮиɪмы 24 чɚɫɚɞоɫɬɭпомɜоɞɟполномоɬɫɭɬɫɬɜииɫɛоɪɚконɬɪольноймочиПоɫлɟэɬоɝожиɜоɬноɟпомɟщɚлоɫьɞомɚшнююклɟɬкɭпɪиёмɚ 5?6 Ⱦɚлɟɟжиɜоɬномɭɜнɭɬɪиɛɪюшинно [8] ɜɜоɞилиɫлɟɞɭɟмоɟɜɟщɟɫɬɜо 0,9% ɪɚɫɬɜоɪɟнɚɬɪия 10 ɭɫɬɚноɜлɟнɚэкɫпɟɪимɟнɬɚльпɪоɜɟɞɟнииɞополниɬɟльныɯɞоɜɚнийɎɚɪмɚɬɟɫɬɪɚмкɚɯпɪоɜɟɞɟэкɫпɟɪɬизыоɛъɟкɬɚɜключɚɜшɟɝоиɫɫлɟɞɭɟмоɟɜɟщɟɫɬɜоПоɫлɟпɪиёмɚɜɟщɟɫɬɜɚжиɜоɬноɟпомɟщɚлоɫьмɟɬɚɛоличɟɫкɭюкɚмɟɪɭ 24 чɚɫɚɫɛоɪɚпоɫɬэкɫпɟɪимɟнɬɚльнойɛиожиɞкоɫɬикоɬопɪоɜоɞилɫяɟɝомɟɬɚɛолиɬоɜɫоɝлɚɫномɟɬоɞикɚмопиɫɚннымнижɟОɛоɪɭɞоɜɚниɟпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚȼыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚȼЭЖɏпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚиɫпользоɜɚноɫлɟɞɭющɟɟоɛоɪɭɞоɜɚниɟжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮɮиɪмы ?Shimadzu LCMC-8050? комплɟкɫɟмɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬоɪомɌипɬоɪɚ ? ɬɪойнойкɜɚɞɪɭпольɞɜойнымиɫɬочникомɯимичɟɫкɚяɚɬмоɫɮɟɪномɞɚɜлɟнииэлɟкɬɪоɫпɪɟйɊɚзɞɟлɟниɟɜɟщɟɫɬɜиɫɯоɞилоɯɪомɚɬоɝɪɚɮичɟɫкойколонкɟмɚɬɟɪиɚл ? нɟɪжɚɜɟющɚяɫɬɚльɯɚɪɚкɬɟɪиɫɬики ? 150 * 3,0 ɋоɪɛɟнɬ ? ȽɚзоɜɚяɯɪомɚɬоɝɪɚɮияȽɚзоɜыймɚɬоɝɪɚɮ ?Agilent 7890A? мɚɫɫɫпɟкɬɪомɟɬɪомколонкɚ 103 нɟполяɪнɚя HP-5ms 28 ? 0,25 кɚчɟɫɬɜɟноɫиɬɟляиɫпользɭɟɬɫяɝɟлийкоɬоɪыйпоɞɚёɬɫяɫкоɪоɫɬью 1,2 ɪɚɛоɬы ? split/splitless, поɬокɚ ? 1:10, зɚɞɟɪжкɚɜключɟния ? поɫлɟɜɜоɞɚ 1 минɭɬɚɌɟмпɟɪɚɬɭɪɚинɬɟɪɮɟйɫɚ 280?ɬɟмпɟɪɚɬɭɪɚинжɟкɬоɪɚ 250?пɪоɝɪɚммиɪɭɟмɚяɬɟмпɟɪɚɬɭɪɚколонки ? Ɋɟжимɪɚɛоɬыɞɟɬɟкɬоɪɚɫɟлɟкɬиɜныймониɬоɪинɝинɬɟɪɜɚл ? 9?13 нɚпɪяжɟниɟɭмножиɬɟлɟɜɟличиныɚɜɬомɚɬичɟɫкойнɚɫɬɪойкиПоɞɝоɬоɜкɚоɛъɟкɬоɜиɫɫлɟɞоɜɚнияПɪиɝоɬоɜлɟниɟɫɬɚнɞɚɪɬноɝоɪɚɫɬɜоɪɚпоɞɛоɪɚɜыɯоɞɚɜɟщɟɫɬɜɚэкɫпɟɪимɟнɬɚльномоɛоɪɭɞоɜɚниипɪиɝоɬоɜлɟнɫɬɚнɞɚɪɬныйɪɚɫɬɜоɪɜɟщɟɫɬɜɚ THJ-2201 ɚцɟɬониɬɪилɟконцɟнɬɪɚции 1 Ⱦɚлɟɟ 0,5 полɭчɟнноɝоɪɚɫɬɜоɪɚпомɟщɚлоɫьɯɪомɚɬоɝɪɚɮичɟɫкɭюɜиɚлкɭɪɚɫɬɜоɪɚɜɜоɞилиинжɟкɬоɪɯɪомɚɬоПɪоɛопоɞɝоɬоɜкɚȼЭЖɏпɪоɛиɪкɭзɚɜинчиɜɚющɟйɫякɪышкойɜмɟɫɬимоɫɬью 10 ɜноɫили 3 ɚнɚлизиɪɭɟмоймочиɞоɛɚɜляли 0,5 ɪɚɫɬɜоɪɚ NaOH ɜыɞɟɪжиɜɚли 2 чиɫɬɭюɫɭɯɭюпɪоɛиɪкɭоɛъёмом 10 3 ɝиɞɪолизɚɬɚмочиȽиɞɪолизɚɬпоɞкиɫляли pH 2?3 ɞоɛɚɜлɟниɟм 250?350 концɟнɬɪиɪоɜɚннойɫолянойкиɫлоɬыпɪоɛиɪкɭɜноɫили 3 ɫмɟɫиизоокɬɚнэɬилɚцɟɬɚɬ (7:1). Помɟщɚли 10 оɪɛиɬɚльныйшɟйкɟɪЦɟнɬɪиɮɭɝиɪоɜɚли 5 3000 ОɬɞɟляличɟɫкийпɟɪɟноɫилипɪоɛиɪкɭɭпɚɪиɜɚнияɭпɚɪиɜɚлиɬокɟɝоɪячɟɝоɜозɞɭɯɚэкɫɬɪɚкɬɭɞоɛɚɜлялиɚцɟɬониɬɪилɚɜɫɬɪяɯиɜɚлиɜиɛɪомикɫɟɪɟɫɟкɚнɚлизиɪоɜɚлиɍɫлоɜияɯɪомɚɬоɝɪɚɮиɪоɜɚнияȼЭЖɏ?10 L/min, Interface Temperature ? 300?, DL Tempera-, Heat Block Temperature ? 400?emperature ? 400?Ɋɟɝиɫɬɪɚциюоɛɪɚɛоɬкɭɯɪомɚɬоɝɪɚɮичɟɫкойинɮоɪмɚцииоɫɭщɟɫɬɜлялипомощьюоɛɟɫпɟчɟния LCsolution (ver. 1.25) [10].Пɪоɛопоɞɝоɬоɜкɚɞɟɪиɜɚɬизɚцияɮлɚконпомɟщɚли 2 мочипɪиɛɚɜляли 150 50% ɪɚɫɬɜоɪɚ NaOH пɟɪɟмɟшиɜɚлиɎлɚконплоɬноɭкɭпоɪиɜɚлипомɟщɚлиɬɟɪмоɛлок 10 60?Поɫлɟоɯлɚжɞɟнияɮлɚконɜɫкɪыɜɚɞоɛɚɜлялиɫɬɚнɞɚɪɬɝɟкɫɟнɚлɚ 100 0,2 пɪиɛɚɜлялиɪɚɫɬɜоɪ HCl pH 2?3 экɫɬɪɚɝиɪоɜɚлиɫмɟɫьюɝɟкɫɚнэɬилɚцɟɬɚɬ (7:1) 5 оɬɞɟлялиɜыпɚɪиɜɚлиɫɭɯоɝооɫɬɚɬɬокɟɬёплоɝоɜозɞɭɯɚ (40?ɫɭɯомɭоɫɬɚɬкɭпɪиɛɚɜляли 500 ɛɟзɜоɞноɝоɚцɟɬонɚɞиɫɬоɝо 2 кɚɪɛонɚɬɚкɚлияɝɟɪмɟɬичнозɚкɪыɜɚлинɚɝɪɟɜɚли 60?ɬɟчɟнии 60 ɬɟɪмоɛлокɟɎлɚконоɯлɚжɞɚлиɊɚɫɬɜоɪпɟɪɟноɫиɮлɚконɜыпɚɪиɜɚлиɬокɟɚзоɬɚɋɭɯойоɫɬɚɬокɞɟɪиɜɚɬизиɪоɜɚнноɝоɪɚɫɬɜоɪялиэɬилɚцɟɬɚɬɚ 1?2 ɜɜоɞилиинжɟкɬоɪɯɪомɚɬомɚɫɫɫпɟкɬɪомɟɬɪɚ [11].Ɋɟɝиɫɬɪɚциюоɛɪɚɛоɬкɭɯɪомɚɬоɝɪɚɮичɟɫкойинɮоɪмɚцииоɫɭщɟɫɬɜлялипомощьюноɝооɛɟɫпɟчɟния AMDIS GC/MS Analysis (ver. 2.66) . 2.66) Ɋɟзɭльɬɚɬыɪɟзɭльɬɚɬɟпɪоɞɟлɚннойɪɚɛоɬыполɭчɟныɫлɟɞɭющиɟпоɞɬɜɟɪжɞɚюɝипоɬɟзɭɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯпоɫлɟпɪиёмɚɜɟщɟɫɬɜɚ THJ-2201 чɟлоɜɟкɚжиɜоɬноɝоȺнɚлизɫɬɚнɞɚɪɬноɝопɪоɜоɞилɫямɟɬоɞɚ MRM-пɟɪɟɯоɞоɜPrecursor ? 233.30, Collision energy ? 15. ɏɪомɚɬоɝɪɚммɚɫɬɚнɞɚɪɬноɝоɪɚɫɬɜоɪɚпɪɟɞɫɬɚɜлɟнɚɫɭнкɟɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryɊиɫɭнокɋɬɚнɞɚɪɬныйɪɚɫɬɜоɪɊиɫɭнокɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪноɝожиɜоɬноɝопɟɪɟɯоɞоɜɊиɫɭнокɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪноɝожиɜоɬноɝопɟɪɟɯоɞоɜPharmacy & Pharmacology V. 5 N 4, 2017Иɫɫлɟɞоɜɚниɟɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪныɯжиɜоɬныɯȼыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоиɫɫлɟɞоɜɚнииɛиожиɞкоɫɬижиɜоɬноиɫпользоɜɚлимɟɬоɞɫоɛɫɬɜɟннымконɬɪолɟммочɭɫоɛиɪɚлиɞɜɚжɞы ? поɫлɟɜɜɟɞɟнияɜɟщɟɫɬɜɚɫооɬɜɟɬɫɬɜɟнноɚнɚлизɚиɫпользоɜɚлɫямɟɬоɞ MRM-пɟɪɟɯоɞоɜнɚɬиɜноɝоɜɟщɟɫɬɜɚɯɚɪɚкɬɟɪныпɚɪɚмɟɬɪы: Product ion ? 361.40, Precursor ? 233.30, Collision Energy ? 15.0. мɟɬɚɛолиɬɚɯɚɪɚкɬɟɪныɫлɟɞɭющиɟпɚɪɚмɟɬɪы: Product ion ? 373.20, Precursor ? 155.20, Collision Energy ? 15.0. полɭчɟнныɯɫлɟɞɭɟɬчɬоконɬɪольɊиɫɭнокМɚɫɫɫпɟкɬɪпикɚɯɚɪɚкɬɟɪноɝоɜɟщɟɫɬɜɚɋɜɟɪɯɭэкɫпɟɪимɟнɬɚльныйлɚɛоɪɚɬоɪноɟжиɜоɬноɟɫнизɭɛиɛлиоɬɟчныйчɟлоɜɟкɊиɫɭнокМɚɫɫɫпɟкɬɪпикɚɯɚɪɚкɬɟɪноɝомɟɬɚɛолиɬɚɜɟщɟɫɬɜɚɋɜɟɪɯɭэкɫпɟɪимɟнɬɚльныйлɚɛоɪɚɬоɪноɟжиɜоɬноɟɫнизɭɛиɛлиоɬɟчныйчɟлоɜɟкмочɟɞɚнноɝо MRM-пɟɪɟɯоɞɚɯɪомɚɬоɝɪɚɮиɪоɜɚниимɚкɫимɚльнɚяинɬɟнɫиɜноɫɬьпикоɜ ? 720 ɬоɝɞɚкɚкɯɪомɚɬоɝɪɚммɟɛиожиɞкоɫɬипоɫлɟпɪиёмɚɜɟщɟɫɬɜɚоɬчёɬлиɜонɚɬиɜноɝоɜɟщɟɫɬɜɚɬɚкжɟиɫкомоɝомɟɬɚɛолиɬɚоɬɜɟɬɫɬɜɭющиɯкɚжɞыйɫɜоɟмɭ MRM ? пɟɪɟɯоɞɭмɚкɫимɚльнɚяинɬɟнɫиɜноɫɬь ? 1 425 000 мɚɬоɝɪɚммыиɫɫлɟɞɭɟмыɯɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪныɯжиɜоɬныɯпоɫлɟɜɟщɟɫɬɜɚ THJ-2201 пɪɟɞɫɬɚɜлɟныɪиɫɭнкɚɯ 3 ɫооɬɜɟɬɫɬɜɟнноȽɚзоɜɚяɯɪомɚɬоɝɪɚɮиямочɟлɚɛоɪɚɬоɪноɝожиɜоɬноɝопоɫлɟпɪиёмɚɜɟщɟɫɬɜɚɪɭжɟныɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryмɟɬɚɛолиɬоɜноɜоɝоɫинɬɟɬичɟɫкоɝокɚннɚɛиноиɞɚчɟлоɜɟкɚлɚɛоɪɚɬоɪнойяɜлɟноɭɫɬɚноɜлɟноɫɭщɟɫɬɜɟнноɟɫɯоɞɫɬɜомɚкɫимɚльнойинɬɟнɫиɜноɫɬьюɬɚɛоличɟɫкиɯпɚɪɚмɟɬɪыɞɟɬɟкɬиɪоɜɚниямɟɬɚɛолиɬоɜɯɪомɚɬоɝɪɚɮиɪоɜɚнияЗɚключɟниɟɍчиɬыɜɚяполɭчɟнныɟɪɟзɭльɬɚɬыэкɫпɟɪимɟнɬɚможноɫɞɟлɚɬьɜыɜоɞпɪиɝоɞноɫɬипɪɟɞложɟннойкомплɟкɫноймɟɬоɞикиɚнɚлизɚоɫнɚщённоɫɬилɚɛоɪɚɬоɪиинɚлилɚɛоɪɚɬоɪныɯжиɜоɬныɯɪɚзноɜиɞноɫɬьɯɪомɚɬоɝɪɚɮичɟɫкоɝооɛоɪɭɞоɜɚнияɌɚкжɟɭчёɬомɜыполнɟнныɯиɫɫлɟɞоɜɚний [13, 14] можноɫɞɟлɚɬьɜыɜоɞзнɚчиɬɟльноймɟжɜиɞоɜойɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯчɟлоɜɟкɚлɚɛоɪɚɬоɪнойɜɟщɟɫɬɜɯимичɟɫкиɫɯоɞныɯиɫɫлɟɞɭɟмымɬочкиɚɜɬоɪоɜиɫɫлɟɞоɜɚниɟяɜляɟɬɫяпɟɪɫпɟкɬиɜнымɬɚккɚкɜнɟɞɪɟнииэкɫпɟɪɬнɭюпɪɚкɬикɭможɟɬɫɭщɟɫɬɜɟнноɫокɪɚɬиɬьɫɟнияноɜоɝопɫиɯоɚкɬиɜноɝоɜɟщɟɫɬɜɚпɟɪɟчɟньзɚпɪɟщённыɯ I позɜоляяполɭчɚɬьмоɞɟльмɟɬɚɛолизмɚиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚɛɟзɫɭɛъɟкɬɚоɬɪɚɜлɟнияоɫноɜɟɛиожиɞкоɫɬɟйлɚɛоɪɚɬоɪныɯжиɜоɬныɯɪɚкɬɟɪныɟнɚɬиɜноɝоɜɟщɟɫɬɜɚоɞноɝомɟɬɚɛолиɬоɜɜɟщɟɫɬɜɚ THJ-2201 мɚɫɫɫпɟкɬɪɚмимɚɫɫɫпɟкɬɪɚмичɟлоɜɟчɟɫкиɯпɪоɝɪɚммноɝокомплɟкɫɚ AMDIS GC/MS Analysis (ver. 2.66.). ɫпɟкɬɪыиɫɫлɟɞоɜɚнноɝонɚɬиɜноɝоɫоɟɞинɟнияɟɝомɟɬɚɛолиɬɚпɪɟɞɫɬɚɜлɟнычɟлоɜɟчɟɫкимизɭльɬɚɬɚмиɪиɫɭнкɚɯɫооɬɜɟɬɫɬɜɟнноОɛɫɭжɞɟниɟполɭчɟнныɯможноɫɞɟлɚɬьɫлɟɞɭющиɟɜыɜоɞыȼЭЖɏɜыɯоɞɚɜɟщɟɫɬɜɚɫɬɚнɞɚɪɬномзɚɞɚнном MRM-пɟɪɟɯоɞɟɫооɬɜɟɬɫɬɜɭɟɬɜыɯоɞɚнɚɬиɜноɝоɜɟщɟɫɬɜɚэкɫпɟɪимɟнɬɚльномчɬоɫɜиɞɟɬɟльɫɬɜɭɟɬɬомчɬоɜыɫокойɞолɟйɜɟɪояɬноɫɬи ? эɬооɞноɜɟщɟɫɬɜоɯɪомɚɬоɝɪɚммконɬɪольноймочипоɫɬэкɫпɟɪимɟнɬɚльнойможноɫɞɟлɚɬьɜыɜоɞчɬоникɚкиɯэнɞоɝɟнныɯɜɟщɟɫɬɜɫооɬɜɟɬɫɬɜɭющиɯпɪɟɞложɟннымпɟɪɟɯоɞɚмɪɭжɟноɯɪомɚɬоɝɪɚммɟпоɫɬэкɫпɟɪимɟнɬɚльноймочиоɬчёɬлиɜонɚɬиɜноɝоɜɟщɟɫɬɜɚ THJ-ɟɝомɟɬɚɛолиɬɚɫооɬɜɟɬɫɬɜɭющиɟпɪɟɞложɟннымпɟɪɟɯоɞɚмкɚчɟɫɬɜɟнныɯоɬличийɫоɫɬɚɜɚмиIntroduction. One of the most acute problems faced cking of new psychoactive sub-stances. Around the world, the number of substances used for recreational purposes is growing. Unfortunately, Rus-sia has not become an exception, scores of new substances used for the purpose of stupefying have been distributed on its territory. Each government struggles with this prob-lem in its own way, which is connected with the peculiari-ties of the legislation in the sphere of restriction of narcotic drugs turnover. Of course, in our country, the ght against cking of intoxicating substances is actively conducted, but it often takes a fairly long time to pass since bition against its synthesis, production, etc. through the A group of scientists at Perm State Pharmaceutical group of scientists at Perm State Pharmaceutical of the turnover of new psychoactive substances is possi-ble through reference to ?analogues of narcotic drugs and psychotropic substances?, the de? nition of which is giv-en in Federal Law No. 3-FZ of 08.01.1998. This group cking in the Rus-the psychoactive effect which they produce.substances.? The results of the research were repeatedly and pharmacological parts. The ?Methodological Rec-used. However, the objects of expert research conducted uids, which To identify the fact of using prohibited substances and, subsequently, to determine the speci c structure Pharmacy & Pharmacology V. 5 N 4, 2017 uoropentyl) -1H-indazole, known under the trivial name of THJ-2201 or AM(N)-2201. Another psychoactive substance known as JWH-018 (IUPAC: ?progenitor? of the test substance. The difference be-indole one [4]. The structural formula of the test sub- uoropentyl)-1H-indazole (THJ-2201)peripheral CB2 receptors [5]. After taking the substance, the following effects are observed: evident sedation, ne and gross motor skills of smooth culty in orientation in space, lowering culty in orientation in space, lowering The aim of this study is to work out a procedure for the determination of the test substance THJ-2201 and its is also the goal of this work. For a relatively rapid perfor- les and and In the proposed study, some methodological recom-of the new synthetic cannabimimetic THJ-2201 in the bi- uid (urine) of laboratory rats are presented for A sam-ment agencies of the Ministry of Internal Affairs of the nity the The experiments were carried out on white mature males of laboratory rats in the Wis-Pharmaceutical Academy in a separate room, at the air The diet was standard for laboratory animals (GOST R for preclinical research in the Russian Federation (GOST To obtain a control uid in the same animal, which rm for 24 hours, with unlimited uid urine control. After that, the animal was placed into a After that, the animal was placed into a with the test substance (0.9% solution of sodium chloride at a dose of 10 mg / kg (the dose was established ex-perimentally while carrying out additional studies on the basis of the ?Pharmatest? as a part of expert evaluation of the object including the test substance). After taking the tal bio-liquid, in which the search for THJ-2201 and its described below.High performance liquid chromatography To carry out the experiment the following rm ?Shimadzu LCMC-8050? in combination with a mass-selective detector. The detector type is a triple graphic column (the material is stainless steel, the char-Gas chromatography (GC). Gas chromatograph ?Agilent 7890A? with Agilent 5975C mass spectrometer, ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological Chemistry ux division was 1:10, the on-delay was 1 minute after the sample insertion. The interface tempera-3-280-10-300. The detector operation mode was selec-voltage on the multiplier was 200 V higher than the auto Preparation of a standard solution. To determine the experimental equipment, a standard solution of THJ-prepared. Further, 0.5 ml of the resulting solution was was injected into the chromatograph injector.Sample preparation for HPLC-MS. 3 ml of the ed up to pH 2-3 by adding 3 ml of isooctane-ethyl acetate (7: 1) was placed into the test tube. Then the test tube was placed on the orbital shaker for 10 minutes, centrifuged for 5 minutes at 3000 rpm. The organic layer was separated, transferred to the glass evaporation tube and evaporated in the stream of hot air. 500 l of acetonitrile was added to the extract, shaken Chromatography conditions for HPLC-MS. Neb-10 L/min, Interface Temperature was 300?, DL Tem-, Heat Block Temperature was 400?emperature was 400?cessing of chromatographic information was carried out using LC solution software (ver 1.25) [10].Sample preparation and derivatization for GC- 2 ml of urine was placed into the vial, 150 NaOH solution was added and mixed. The bottle was 60?C. After cooling the vial was opened, a hexenal stan-n-hexane-ethyl acetate (7 : 1) in a 5 ml portion. The top for 60 minutes in a fuser. The bottle was cooled. The a stream of nitrogen. The dry residue of the derivatized ter injector [11].formation was carried out using the AMDIS GC / MS Analysis software (ver.2.66) [12]. rming the hypothesis of the sim- les after administration of THJ-361.40, precursor was 233.30, collision energy was 15. uid of laboratory animals.High performance liquid chromatography. In uidity of the animal, a comparison the substance (Figure 4 and Figure 3, respectively). The MRM-transitions method was used for the analysis. The lision energy is 15.0. The following parameters are typi-155.20, collision energy is 15.0. From the data obtained it follows that in the ?control matography were found out (the maximum intensity of the peaks was 720 units), whereas on the chromatogram of uid collected after taking the substance, the peak of the native substance was clearly visible, as well as the peak of the desired metabolite, corresponding to each of its MRM-transitions (the maximum intensity was 1,425,000 uid of laboratory animals before and after taking THJ-2201 are shown in Figures 3 and 4, respectively.Gas chromatography. In the urine of a laborato-of the THJ-2201 substance with mass spectra coincid-the database of the AMDIS GC / MS Analysis software package (ver. 2.66.). The mass spectra of the sample for respectively.We can draw the following conclusions the peaks of the native substance THJ-2201 and its Pharmacy & Pharmacology V. 5 N 4, 2017Figure 2 ? Standard solution THJ-2201. MRM analysisFigure 3 ? A sample of the biological uid of a laboratory animal before taking THJ-2201. MRM Transition MethodFigure 4 ? A sample of the biological uid of a laboratory animal after taking THJ-2201. MRM Transition MethodɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryFigure 5 ? Mass spectrum of the peak, characteristic for the native substance THJ-2201. Above ? experimental (laboratory animal), below ? library (man)Figure 6 ? Mass spectrum of the peak, characteristic for the metabolite of substance THJ-2201. Above ? no qualitative differences between the ionic composi-noid THJ-2201 in humans and in laboratory rats have tensity in different metabolic pro les was established;Taking into account the obtained results Taking into account the previous studies [13, 14], cant degree of les and laboratory rats? for substances chemically similar to the From the point of view of the authors, the study is cantly reduce the time of in-troducing a new psychoactive substance into the list of prohibited substances (List I of the National Assembly and the Law), making it possible to obtain a model of metabolism of the test substance without a poisoning uids of laboratory an-Pharmacy & Pharmacology V. 5 N 4, 2017ȻиɛлиоɝɪɚɮичɟɫкийɎɟɞɟɪɚльныйзɚконянɜɚɪянɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜɚɯпɫиɯоɬɪопныɯɜɟщɟɫɬɜɚɯПоɫɬɚноɜлɟниɟПɪɚɜиɬɟльɫɬɜɚ 30 1998 681 ?ɭɬɜɟɪжɞɟниипɟɪɟчнянɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜпɪɟкɭɪɫоɪоɜпоɞлɟжɚщиɯконɬɪолюɊоɫɫийɫкойɎɟɞɟɪɚцииɌɟмɟɪɞɚшɟɜКиɫɟлёɜɚКолычɟɜКɚльницкийȼЭЖɏ - ОПɊȿȾȿЛȿНИȿНȿКОɌОɊЫɏНȺɊКОɌИЧȿɋКИɏПɊИɊОȾНОȽОɋИНɌȿɌИЧȿɋКОȽОПɊОИɋɏОЖȾȿ ? ПɊОИЗȼОȾНЫɏ N-ИНȾОЛИЛКȿɌОНОȼȺМИНОȺɊИЛКȿɌОНОȼКИɋЛОɌɌɊОПȺНОȼЫɏ // ȺнɚлиɬикɚконɬɪольɋоɫноɜȻɭлыɝинɚОɋНОȼНЫȿɏȺɊȺКɌȿɊИɋɌИКИНОȼОȽОɋИНɌȿɌИЧȿɋКОȽОНȺɎɌȺЛИНИНȾȺЗОЛМȿɌȺНОН THJ-2201 // НɚɪколоɝияCornelius H., Schoeder C.T., Pillaiyar T., Burkhard M., M?ller C.E. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS IDENTIFIED AS CONSTITUENTS OF SPICE // Forensic Toxicology34 (2). P. 329?343.10.1007/s11419-016-0320-2THJ-2201 // psychonautwiki.org URL: https://psychonautwiki.org/wiki/THJ-2201.METABOLIC CAGE // http://www.openscience.ru URL: http://www.openscience.ru/index.ɊɭкоɜоɞɫɬɜопɪоɜɟɞɟниюɞоклиничɟɫкиɯиɫɫлɟɞоɜɚнийлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜȽɪиɮИнɮоɪмɚционноɟɪɭжɟниɟɫинɬɟɬичɟɫкиɯкɚннɚɛимимɟɬикоɜнɚɪкоɬичɟɫкиɯпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜмɟɬɚɛолиɬоɜмочɟɜолоɫɚɯноɝɬяɯмɟɬоɞɚмижиɞкоɫɬнойɯɪомɚɬоɝɪɚɮиимɚɫɫɫпɟкɬɪомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмМиниɫɬɟɪɫɬɜоЗɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииНɚционɚльныйнɚɭчныйцɟнɬɪнɚɪколоɝииLCsolution Software // www.ssi.shimadzu.com URL: http://www.ssi.shimadzu.com/products/product.cfm?pro-КɚɬɚɟɜМɟлɟнɬьɟɜȾɜоɪɫкɚяМȿɌȺȻОЛИɌОȼМОЧȿȻɭɬлɟɪоɜɫкиɟɫооɛщɟния. 2013. Vol. 36. No. 10. P. 29?36.Мɚлкоɜɚɏɚɪɚкɬɟɪиɫɬикɚмɟɬɚɛолизмɚɪɚзɪɚɛоɬкɚмɟɬоɞикиɫинɬɟɬичɟɫкоɝокɚннɚɛиноиɞɚ pb-22 мочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯ // ȾоɫɬижɟнияпɪоɛлɟмынɚɭкиНɚɭчныйжɭɪнɚлМɚлкоɜɚɏȺɊȺКɌȿɊИɋɌИКȺМȿɌȺȻОЛИЗМȺɊȺЗɊȺȻОɌКȺМȿɌОȾИКИОПɊȿȾȿЛȿНИЯɋИНɌȿɌИЧȿɋКОȽО AB-PINACA МОЧȿЛȺȻОɊȺɌОɊНЫɏЗɞоɪоɜьɟоɛɪɚзоɜɚниɟɜɟкɟ. 2016. Vol. 18. No. 10. . 113?124.Referencesencesstvah i psihotropnyh veshchestvah? [?On Narcotic Drugs and Psychotropic Substances?]. (In Russ.)2. Postanovlenie Pravitelstva RF ot 30 iyunya 1998 g N 681 [Resolution of the Government of the Russian Feder--psychotropic substances and their precursors subject to control in the Russian Federation?]. (In Russ.)3. Temerdashev A.Z., Kiseleva N.V., Kolychev I.A., Kalnitsky A.G. GH-MS I VEZHKH-MS - OPREDELENIE NE-KOTORYH NARKOTICHESKIH SREDSTV PRIRODNOGO I SINTETICHESKOGO PROISKHOZHDENI-YA - PROIZVODNYH N-ALKIL-3-INDOLILKETONOV -AMINOARILKETONOV P-AMINOBENZOJNYH KISLOT KANNABINOIDOV I TROPANOVYH ALKALOIDOV [GC-MS AND HPLC-MS - DETERMINA-TION OF SOME DRUGS OF NATURAL AND SYNTHETIC ORIGIN - DERIVATIVES OF N-ALKYL-3-IN-DOLYLKETONS, -AMINOARYLCRETHONES, P-AMINOBENZOIC ACIDS, CANNABINOIDS AND TROPANIC ALKALOIDS]. Analitika i contrololAnalytics and Control]. 2012. N 3. P. 240?247. (In Russ.)Vasiliev AB, Sosnov DA, Bulygina I.E. IDENTIFIKACIYA I OSNOVNYE HARAKTERISTIKI NOVOGO SINTETICHESKOGO KANNABINOIDA NAFTALIN-1-IL 1-PENTIL-1N-INDAZOL-3-IL METANON THJ-2201 [IDENTIFICATION AND MAIN CHARACTERISTICS OF NEW SYNTHETIC CANNABINOID (NAPHTHALIN-1-IL) (1-PENTIL-1H-INDAZOL-3-IL) METHANON THJ-2201]. Nakrologiya [Nakropologi- 2014. No. 5 (149). P. 79?82. (In Russ.)Cornelius H., Schoeder C.T., Pillaiyar T., Burkhard M., M?ller C.E. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS IDENTIFIED AS CONSTITUENTS OF SPICE. Forensic Toxicology. 2016. 34 (2). P. 329-343. DOI: 10.1007 / s11419-016-0320-2.THJ-2201. psychonautwiki.org URL: https://psychonautwiki.org/wiki/THJ-2201.METABOLIC CAGE. http://www.openscience.ru URL: http://www.openscience.ru/index.ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryMironov A.N. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [A guide to con- guide to con-Мoscow: Grif and To], 2012. 751 p. (In Russ.) i s mass-spektrometricheskim de-i s mass-spektrometricheskim de-and their metabolites in urine, hair and nails by liquid chromatography with mass spectrometric detection?]. Ministerstvo Zdravoohraneniya Rossijskoj Federacii Nacionalnyj nauchnyj centr narkologii [Ministry of Health of the Russian Federation, National Scienti? c Center of Narcology]. 2014. (In Russ.)LCsolution Software. www.ssi.shimadzu.com URL: http://www.ssi.shimadzu.com/products/product.cfm?pro-Kataev S.S., Melentiev A.B., Dvorskaya O.N. IDENTIFIKACIYA METABOLITOV KANNABIMIMETIKA PB-22 V MOCHE [IDENTIFICATION OF METABOLITES OF PB-22 CANNABYMETHYME IN URINE]. Butlerovskie soobshcheniyaovskie soobshcheniyaButlerov Communications]. 2013. Vol. 36. No. 10. P. 29?36. (In Russ.)Apushkin D.Yu., Andreev A.I., Malkova T.L. Harakteristika metabolizma i razrabotka metodiki opredeleniya .L. Harakteristika metabolizma i razrabotka metodiki opredeleniya opment of a technique for the determination of synthetic cannabinoid pb-22 in urine of laboratory animals]. Dos-tizheniya i problemy sovremennoj nauki [Achievements and problems of modern science]. SPb Nauchnyj zhurnal Globus [SPb.: Scienti? c journal ??Globus??]. 2016. P. 102?107. (In Russ.)Apushkin D.Yu., Malkova T.L. Harakteristika metabolizma i razrabotka metodiki opredeleniya sinteticheskogo .L. Harakteristika metabolizma i razrabotka metodiki opredeleniya sinteticheskogo method of determining ab-pinaca synthetic cannabinoid in uroline of laboratory animals]. Zdorove i obrazovanie ove i obrazovanie . 2016. Vol. 18. No. 10. P. 113?124. (In Russ.)КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜȺɜɬоɪы ? млɚɞшийнɚɭчныйɫоɬɪɭɞникнɚɭчноɝооɬɞɟлɚПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟнɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɪɚзɪɚɛоɬкɚмɟɬоɞикопɪɟɞɟлɟнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɛиолоɝичɟɫкиɯжиɞкоɫɬяɯɜыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚɮияɝɚзоɜɚяɯɪомɚɬоɝɪɚɮияɯɟмоинɮоɪмɚɬикɚмолɟкɭмоɞɟлиɪоɜɚниɟМɚлкоɜɚɌɚмɚɪɚЛɟониɞоɜнɚ ? ɞокɬоɪɮɚɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪзɚɜɟɞɭющийкɚɮɟɞɪойɬокɫиколоɝичɟɫкойПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟнɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɪɚзɪɚɛоɬкɚɫоɜɟɪшɟнɫɬɜоɜɚниɟмɟɬоопɪɟɞɟлɟниялɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɬомчиɫлɟɬокɫиколоɝичɟɫкоɟзнɚчɟниɟиɫɫлɟɞоɜɚниɟпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜоɛɟɫпɟчɟниɟкɚчɟɫɬɜɚɚнɚлиɬичɟɫкиɯиɫɫлɟɞоɜɚнийПоɫɬɭпилɚɪɟɞɚкциюПɪиняɬɚпɟчɚɬи ict of interest ict of interest.Apushkin Danila Yurievich junior research as- c department, Perm State Pharma-ceutical Academy. Research interests: working out the uids, high-performance liquid chromatogra-phy, gas chromatography, chemoinformatics, molecular Malkova Tamara Leonidovna Doctor of Sciences (Pharmacy), Professor, Head of the Department of Toxi-cological Chemistry, Perm State Pharmaceutical Acade-my. Research interests: working out thedetermination of medicinal products, including those of cance, the study of new psychoactive ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryциɬиɪоɜɚнияМɚлкоɜɚɏȺɊȺКɌȿɊИɋɌИКȺМȿɌȺȻОЛИЗМȺɊȺЗɊȺȻОɌКȺМȿɌОȾИКОПɊȿȾȿЛȿНИЯɋИНɌȿɌИЧȿɋКОȽО THJ-2201МОЧȿЛȺȻОɊȺɌОɊНЫɏɎɚɪмɚцияɮɚɪмɚколоɝияМɚлкоɜɚFor citation:Apushkin D. Yu., Malkova T.L. CHARACTERISTICS OF METABOLISM AND WORKING OUT THE METHODS OF DETERMINATION OF SYNTHETIC CANNABINOID THJ-2201 IN THE URINE OF LABORATORY ANIMALS.Pharmacy & Pharmacology. ɍȾКˈʤˀʤК˃ʫˀʰˁ˃ʰКʤʺʫ˃ʤʥОЛʰʯʺʤˀʤʯˀʤʥО˃Кʤʺʫ˃ОʪʰКОʿˀʫʪʫЛʫʻʰЯˁʰʻ˃ʫ˃ʰЧʫˁКОʧО THJЛʤʥОˀʤ˃ОˀʻˏˈʮʰʦО˃ʻˏˈМɚлкоɜɚɎȽȻОɍПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияМинзɞɪɚɜɚɊоɫɫииɊоɫɫияПɟɪмьПолɟɜɚяпɪɟɞложɟннойɫɬɚɬьɟɜопɪоɫыизɭчɟниямɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛиноɪɚɛоɬɟпɪɟɞɫɬɚɜлɟныɫинɬɟɬичɟɫкомкɚннɚɛиноиɞɟ 3-(Нɚɮɬɚлинилокɫомɟɬилинɞɚзол (THJ-2201), ɬɚкжɟпɪоɞɭкɬɚɯмɟɬɚɛолизмɚоɪɝɚнизмɟлɚɛоɪɚɬоɪныɯɫɬокɚ Wistar, пɪиɜɟɞɟныɫпɟкɬɪыɯɪомɚɬоɝɪɚммыɜɟщɟɫɬɜɚ (THJ-2201), полɭчɟнныɟпомощьюмɟɬоɞоɜɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɫɟлɟкɬиɜнойȼЭЖɏɝɚзоɜойɯɪомɚɬоɝɪɚɮииɫɟлɟкɬиɜнойɞɟɬɟкциɟйɪɚɛоɬɟпɪɟɞɫɬɚɜлɟнɚкомплɟкɫнɚямɟɬоɞикɚкɚчɟɫɬɜɟнноɝоопɪɟɞɟлɟниякɚннɚɛимимɟɬикɚ THJ-2201 мɟɬоɞикɚполɭчɟниямоɞɟлимɟɬɚɛоличɟɫкоɝоиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚкоɬоɪɚяможɟɬполɟзнойзɚɞɚччɟɫɬɜɟнноɝоопɪɟɞɟлɟнияоɛнɚɪɭжɟнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɛиолоɝичɟɫкиɯоɛъɟкɬɚɯцɟлɟйɫɭɞɟɛноɯимичɟɫкоɝоЦɟльюнɚɫɬоящɟйɪɚɛоɬыяɜлялɚɫьɪɚзɪɚɛоɬкɚмɟɬоɞикиопɪɟɞɟлɟнияиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚ (THJ-2201) мɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯɬɚкжɟиɫɫлɟɞоɜɚниɟоɫоɛɟнноɫɬɟймɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛиноиɞоɜцɟломМɚɬɟɪиɚлымɟɬоɞыпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚɛылоиɫпользоɜɚноɫлɟɞɭющɟɟоɛоɪɭɞоɜɚниɟжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮɮиɪмы ?Shimadzu комплɟкɫɟɫɟлɟкɬиɜнымɞɟɬɟкɬоɪомɌипɞɟɬɟкɬоɪɚкɜɚɞɪɭпольɞɜойнымиɫɬочникомɯимичɟɫкɚяɚɬмоɫɮɟɪномɞɚɜлɟнииэлɟкɬɪоɫпɪɟйɊɚзɞɟлɟниɟщɟɫɬɜпɪоиɫɯоɞилоɯɪомɚɬоɝɪɚɮичɟɫкойколонкɟ ? нɟɪжɚɜɟющɚяɫɬɚльɯɚɪɚкɬɟɪиɫɬики ? 150 ɋоɪɛɟнɬ ? оɛɪɚщённоИɫɫлɟɞоɜɚнияпɪоɜɟɞɟныɝɚзоɜомɯɪомɚɬо ?Agilent 7890A? ɫпɟкɬɪомɟɬɪом Agilent 5975C колонкой 103 нɟполяɪной HP-5ms 28 ? 0,25 Жиɜоɬныɟ ? полоɜозɪɟлыɟɫɚмцыɛɟлыɯлɚɛоɪɚɬоɪныɯɫɬокɚ Wistar, ɜозɪɚɫɬмɟɫяцɟɜмɚɫɫɚ 190Ɋɟзɭльɬɚɬыоɛɫɭжɞɟниɟɪɟзɭльɬɚɬɟпɪоɜɟɞённыɯиɫɫлɟɞоɜɚнийɛылɚɪɚзɪɚɛоɬɚнɚплɟкɫнɚямɟɬоɞикɚопɪɟɞɟлɟнияɫинɬɟɬичɟɫкоɝокɚннɚɛимиммɟɬикɚ THJ-2201 мɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯполɭчɟныɯɪомɚɬоɝɪɚммыɫпɟкɬɪымɟɬɚɛоличɟɫкоɝоɜоɬныɯпомощьюмɟɬоɞоɜȼЭЖɏɬɚкжɟɭɫɬɚноɜлɟнɚзнɚчиɬɟльнɚяɫɯожɟɫɬьмɟɬɚɛоличɟɫкиɯпɪоɮилɟйиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚчɟлоɜɟкɚжиɜоɬныɯЗɚключɟниɟɫɞɟлɚныɜыɜоɞыпɪиɝоɞноɫɬипɪɟɞложɟннойкомплɟкɫноймɟɬоɞикиɭɫлоɜияɯлɚɛоɪɚɬоɪиизнɚчиɬɟльноймɟжɜиɞоɜойɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯпɪоɮилɟйчɟлоɜɟкɚлɚɛоɪɚɬоɪнойɜɟщɟɫɬɜɯимичɟɫкиɛлизкиɯиɫɫлɟɞɭɟмымКлючɟɜыɟɫлоɜɚНɚɮɬɚлинилокɫомɟɬилɮɬоɪпɟнɬилинɞɚзоллɚɛоɪɚɬоɪныɟжиɜоɬныɟмɟɬɚɛолиɬыɫинɬɟɬичɟɫкиɟкɚннɚɛиноиɞыȼЭЖɏPharmacy & Pharmacology V. 5 N 4, 2017ȼɜɟɞɟниɟОɞнойɫɚмыɯоɫɬɪыɯпɪоɛлɟмɬоɪымиɫɬолкнɭлоɫьчɟлоɜɟчɟɫɬɜопоɫлɟɞниɟɞɜɚɞɟɫяɬкɚяɜляɟɬɫяпɪоɛлɟмɚнɟлɟɝɚльноɝоɫинɬɟзɚоɛоɪоɬɚпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɜɫɟмɭмиɪɭɜɟщɟɫɬɜкоɬоɪыɟиɫпользɭюɬɫяɪɟкɪɟɚционныɯɫожɚлɟниюɊоɫɫияɫɬɚлɚиɫключɟниɟмɬɟɪɪиɬоɪииɪɚɫпɪоɫɬɪɚнɟниɟɞɟɫяɬкиɜɟщɟɫɬɜиɫпользɭɟмыɯоɞɭɪмɚниɜɚниякɚжɞомɝоɫɭɞɚɪɫɬɜɟɫɜоɟмɭɛоɪюɬɫяэɬойпɪоɛлɟмойчɬоɫɜязɚнооɫоɛɟнноɫɬямизɚконоɞɚɬɟльɫɬɜɚɫɮɟɪɟоɛоɪоɬɚнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜȻɟзɭɫлоɜноɫɬɪɚнɟнɟзɚконнымоɛоɪоɬомоɞɭɪмɚниɜɚющиɯɜɟщɟɫɬɜɚкɬиɜноɜɟɞёɬɫяоɞнɚкозɚчɚɫɬɭюпɪоɯоɞиɬɞоɜольноɛольшойоɬɪɟзокмомɟнɬɚɪɭжɟнияноɜоɝоɫинɬɟɬичɟɫкоɝоɜɟщɟɫɬɜɚɟɝопɪɟɬɚɫинɬɟзɭпɪоизɜоɞɫɬɜɭчɟɪɟзɜключɟниɟконɬɪолиɪɭɟмыɯɜɟщɟɫɬɜȽɪɭппɚПɟɪмɫкойɝоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚцɟɜɬичɟɫкойɚкɚɞɟмииɛолɟɟ 7 ɜоɞиɬиɫɫлɟɞоɜɚнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɞɟйɫɬɜɭющɟɟɫɬɪɚнɟзɚконоɞɚɬɟльɫɬɜо [1, 2]. ɊоɫɫииоɛоɪоɬɚпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɜозможночɟɪɟзоɬнɟɫɟниɟɚнɚлоɝɚмнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜопɪɟɞɟлɟниɟкоɬоɪыɯпɪиɜɟɞɟноɎɟɞɟɪɚльномзɚконɟ 3- 08.01.1998 ЭɬɚɝɪɭппɚɜключɚɟɬɫɟɛяɚнɚлоɝинɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜзɚпɪɟщɟнныɟоɛоɪоɬɚɊоɫɫийɫкойɎɟɞɟɪɚцииɜɟщɟɫɬɜɚɫинɬɟɬичɟɫкоɝоɟɫɬɟɫɬɜɟнноɝопɪоиɫɯожɞɟнияɜключɟнныɟПɟɪɟчɟньнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜпɪɟкɭɪɫоɪоɜпоɞлɟжɚщиɯконɬɪолюɊоɫɫийɫкойɎɟɞɟɪɚцииɯимичɟɫкɚяɫɬɪɭкɬɭɪɚɫɜойɫɬɜɚкоɬоɪыɯɫɯоɞныɯимичɟɫкойɫɬɪɭкɬɭɫɜойɫɬɜɚминɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜɯоɬɪопныɯɜɟщɟɫɬɜпɫиɯоɚкɬиɜноɟкоɬоɜоɫпɪоизɜоɞяɬНɚкоплɟнныйпозɜолилɫɮоɪмиɪоɜɚɬьМɟɬоɞичɟɫкиɟɪɟкомɟнɞɚциииɫɫлɟɞоɜɚниюпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜпɪоцɟɞɭɪɟоɬнɟɫɟнияɚнɚлоɝɚмнɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопɜɟщɟɫɬɜɊɟзɭльɬɚɬыиɫɫлɟɞоɜɚнийнɟоɞнокɪɚɬноɞоклɚɞыɜɚлиɫьконɮɟɪɟнцияɯɮоɪɭмɚɯCHARACTERISTICS OF METABOLISM AND WORKING OUT THE METHODS OF DETERMINATION OF SYNTHETIC CANNABINOID 2201 IN THE URINE OF LABORATORY ANIMALSD.Yu. Apushkin, T.L. Malkova Perm State Pharmaceutical Academy, The proposed article touches upon the study of metabolism of new synthetic cannabinoids. In the work the data uoropentyl)-1H-indazole (THJ-2201), as well as the prod-ucts of its metabolism in the laboratory rats of the Wistar line are given, i. e. Mass spectra and chromatograms of the native substance (THJ-2201) obtained by high-performance liquid chromatography with mass-selective detection (HPLC-MS) and gas chromatography with mass-selective detection (GC-MS) are given. The paper presents a complex technique for qualitative determination of cannabimimetics THJ-2201 and methods for obtaining a metabolic prosubstances in biological objects for the purposes of forensic analysis. equipment was used for the experiment: a liquid chromatograph from the tion with a mass-selective detector. The detector type is a triple quadrupole with a double ionization source (chemical ionization at atmospheric pressure and electrospray). The separation of the substances occurred in a chromatograph-ic column (the material is stainless steel, the characteristics are: 150 * 3.0 mm, Luna 3uC18 (2), 100A). The Sorbent is reversed-phase. The investigations were carried out on Agilent 7890A gas chromatograph with Agilent 5975C mass spectrometer and a 103 polar HP-5ms column of 28 m ? 0.25 mm. The animals were mature male white laboratory rats of the Wistar line, aged 4As a result of the studies, a comprehensive methodology for determining the synthetic cannabimimetics of THJ-2201 and its metabolites in the urine of laboratory animals was developed, chromatograms and mass spectra of the metabolic pro le of animals were obtained by HPLC-MS and GC-MS methods, and the similarity of the metabolic pro les of the studied substances in The conclusions were made about the suitability of the proposed cant degree of interspeci c simi-larity of human metabolic pro les and laboratory rats? for substances chemically close to the studied. uoropentyl)-1H-indazole, THJ-2201, laboratory animals, me-ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryнɚɯоɞилипоɞɞɟɪжкɭпɪɟɞɫɬɚɜиɬɟлɟйпɪɚɜооɯɪɚниэкɫпɟɪɬныɯɫлɭжɛɪɟкомɟнɞɚцииɪɚзɪɚɛоɬɚныоɛъɟкɬоɜиɫɫлɟɞоɜɚнияпɪɟɞɫɬɚɜляющиɯщɟɫɬɜɟнныɟɞокɚзɚɬɟльɫɬɜɚɫɭɛɫɬɚнцииɫмɟɫимɚɫɫыɜɟɪояɬноɫоɞɟɪжɚщиɟɚнɚлоɝинɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜɊɚзɪɚɛоɬɚнныйɚлɝоɪиɬмиɫɫлɟɞоɜɚнияɜключɚɟɬɯимичɟɫкɭюɮɚɪмɚколоɝичɟɫкɭюМɟɬоɞичɟɫкиɯɪɟкомɟнɞɚцияɯпоɞɪоɛноопиɫɚнопочɟмɭиɫпользɭɟɬɫяɬɚкойпоɞɯоɞОɞнɚкооɛъɟкɬɚмиэкɫпɟɪɬноɝоиɫɫлɟɞоɜɚнияпɪоɜоɞимоɝоɪɭжɟнияпɫиɯоɚкɜɟщɟɫɬɜɬолькоɜɟщɟɫɬɜɟнɞокɚзɚɬɟльɫɬɜɚнɟɛиолоɝичɟɫкоɝоɯɚɪɚкɬɟɪɚɛиолоɝичɟɫкиɟжиɞкоɫɬичɬонɚиɛолɟɟɜоɫɬɪɟɛоɜɚнопɪоɜɟɞɟниимɟɞицинɫкоɝооɫɜиɞɟɬɟльɫɬɜоɜɚнияɭпоɬɪɟɛляющиɯоɞɭɪмɚниɜɚющиɟɜɟщɟɫɬɜɚЧɬоɛыɭɫɬɚноɜиɬьɮɚкɬɭпоɬɪɟɛлɟниязɚпɪɟɜɟщɟɫɬɜɜпоɫлɟɞɫɬɜииопɪɟɞɟлиɬьконɫɬɪɭкɬɭɪɭиɫɫлɟɞɭɟмоɝопɫиɯоɚкɬиɜноɝоɜɟщɟɫɬɜɚпɪимɟняюɬɫяɯɪомɚɬоɝɪɚɮичɟɫкиɟмɟɬоɚнɚлизɚɛиолоɝичɟɫкиɯоɛъɟкɬоɜɬомȼЭЖɏɜыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚɮиямɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬиɪоɜɚниɟмɝɚзоɜɚяɯɪомɚɬоɝɪɚɮиямɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬиɪоɜɚниɟмoxicological ChemistryОɞнимɫɚмыɯпɪɟɞɫɬɚɜиɬɟлɟйɞɚнноɝоклɚɫɫɚпɫиɯоɬɪопныɯɜɟщɟɫɬɜяɜляɟɬɫя 3-(Нɚɮɬɚлинилокɫомɟɬилɮɬоɪинɞɚзолизɜɟɫɬноɟпоɞɬɪиɜиɚльнымнɚзɜɚниɟм THJ-2201 AM(N)-2201. ?ПɪɚɪоɞиɬɟиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚможноɫчиɬɚɬьɞɪɭɝоɟпɫиɯоɚкɬиɜноɟɜɟщɟɫɬɜоизɜɟɫɬноɟпоɞнɚзɜɚниɟмJWH-018 (IUPAC: (1-нɚɮɬоилинɞол)), оɬличиɟзɚключɚɟɬɫяинɞольноɝоинɞозольноɟ ɋɬɪɭкɬɭɪнɚяɮоɪмɭлɚиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚпɪɟɞɫɬɚɜлɟнɚɪиɫɭнкɟɊиɫɭнокɋɬɪɭкɬɭɪнɚяɮоɪмɭлɚилокɫомɟɬилɮɬоɪпɟнɬилинɞɚзолɚɫɜоимɮɚɪмɚколоɝичɟɫкимɫɜойɫɬɜɚмɞɚнноɟɜɟщɟɫɬɜояɜляɟɬɫяполнымɚɝониɫɬомцɟнɬɪɚльныɯпɟɪиɮɟɪичɟɫкиɯ CB2 ɪɟцɟпɬоɪоɜ [5]. Поɫлɟпɪиёмɚɜɟщɟɫɬɜɚнɚɛлюɞɚюɬɫяɫлɟɞɭющиɟэɮɮɟкɜыɪɚжɟннɚяɫɟɞɚцияпоɬɟɪяконɬɪолямɟлкойкɪɭпноймоɬоɪикиɝлɚɞкиɯɬɪɭɞноɫɬиɟнɬɚциɟйпɪоɫɬɪɚнɫɬɜɟɫнижɟниɟɚɪɬɟɪиɚльноɝоɞɚɜлɟнияɬошноɬɚнɚɪɭшɟнияɞɪɭɝиɟ [5]. Цɟлью ɞɚнноɝоиɫɫлɟɞоɜɚнияяɜляɟɬɫяɛоɬкɚмɟɬоɞикиопɪɟɞɟлɟнияиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚɟɝомɟɬɚɛолиɬоɜмочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯɜыяɜлɟниɟɯɚɪɚкɬɟɪныɯмɟɬɚɛолиɬоɜɭкɚзыɜɚɟɬɮɚкɬɭпоɬɪɟɛлɟниязɚпɪɟщённоɝоɜɟщɟɫɬɜɚкɪомɟɬоɝоизɭчɟниɟмɟɬɚɛолизмɚɫинɬɟɬичɟɫкиɯкɚннɚɛимимɟɬикоɜцɟломɬɚкжɟляɟɬɫяɪɚɛоɬыоɬноɫиɬɟльноɛыɫɬɪоɝоɜыполнɟниякɚчɟɫɬɜɟнноɝоɚнɚлизɚмɟɬɚɛоличɟɫкиɯɫинɬɟзиɪоɜɚнныɯпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜможноиɫпользоɜɚɬьмɟɬɚɛоличɟɫкиɟкɚмɟɪылɚɛоɪɚɬоɪжиɜоɬныɯ ȼ пɪɟɞложɟнномиɫɫлɟɞоɜɚнииɪɚɫɫмоɬɪɟниɟпɪɟɞɫɬɚɜлɟнынɟкоɬоɪыɟмɟɬоɞичɟɫкиɟɪɟкомɟнɞɚмɟɬоɞоɜȼЭЖɏкɚчɟɫɬɜɟнноɝоопɪɟɞɟлɟниямɟɬɚɛолиɬоɜноɜоɝоɫинɬɟɬичɟɫкоɝокɚннɚɛимимɟɬикɚ THJ-2201 ɛиолоɝичɟɫкойжиɞкоɫɬимочɟлɚɛоɪɚɬоɪныɯМɚɬɟɪиɚлымɟɬоɞыИɫɫлɟɞɭɟмоɟɜɟщɟɫɬɜоɜɟщɟɫɬɜɚпɪɟɞоɫɬɚɜлɟнпɪɚɜооɯɪɚниɬɟльМиниɫɬɟɪɫɬɜɚȼнɭɬɪɟнниɯȾɟлɊоɫɫийɫкойɎɟɞɟɪɚцииɛɚзɭɊɟɝионɚльноɝоɫлɟɞоɜɚɬɟльɫкоɝоЦɟнɬɪɚɎɚɪмɚɬɟɫɬɭɫɬɚноɜɯимичɟɫкойɫɬɪɭкɬɭɪыопɪɟɞɟлɟнияɯимичɟɫкойɛлизоɫɬиɜɟщɟɫɬɜɚмпоимɟноɜɚннымɋпиɫкɟ I нɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜɬɚкжɟɭɫɬɚноɜлɟнияɚнɚлоɝичноɫɬизɚпɪɟщённымɜɟщɟɫɬɜɚмЛɚɛоɪɚɬоɪныɟжиɜоɬныɟЭкɫпɟɪимɟнɬыпɪоɜɟɞɟныɛɟлыɯполоɜозɪɟлыɯɫɚмцɚɯɬоɪныɯɫɬокɚ Wistar ɜозɪɚɫɬɟмɟɫямɚɫɫой 180-250 ЖиɜоɬныɟɫоɞɟɪжɚлиɫьɬɟɪɪиɬоɪииɜиɜɚɪияɎȽȻОɍПȽɎȺМинзɞɪɚɜɚɊоɫɫииоɬɞɟльнойкомнɚɬɟɬɟмпɟɪɚɬɭɪɟɜозɞɭ 22?2 ?ɜлɚжноɫɬиɜозɞɭɯɚ 55?-65%. Ⱦиɟɬɚ ? ɫɬɚнɞɚɪɬнɚялɚɛоɪɚɬоɪныɯжиɜоɬныɯȽОɋɌɫоɝлɚɫнолɚɛоɪɚɬоɪнойпɪɚкɬикипɪоɜɟɞɟнииɞоклиничɟɫкиɯиɫɫлɟɞоɜɚнийȽОɋɌPharmacy & Pharmacology V. 5 N 4, 2017ɋɯɟмɚэкɫпɟɪимɟнɬɚполɭчɟнияконɬɪольпоɫɬэкɫпозиционнойɛиожиɞкоɫɬиоɞноɝоɬоɝожиɜоɬноɝочɬонɟоɛɯоɞимоɫопоɫɬɚɜлɟɪɟзɭльɬɚɬоɜплɚниɪоɜɚнииэкɫпɟɪимɟнɬɚпользоɜɚлɚɫьɫлɟɞɭющɚяɫɯɟмɚɪɚɫɫɚɞкиɜоɬноɟпомɟщɚлоɫьмɟɬɚɛоличɟɫкɭюкɚмɟɪɭɮиɪмы 24 чɚɫɚɞоɫɬɭпомɜоɞɟполномоɬɫɭɬɫɬɜииɫɛоɪɚконɬɪольноймочиПоɫлɟэɬоɝожиɜоɬноɟпомɟщɚлоɫьɞомɚшнююклɟɬкɭпɪиёмɚ 5?6 Ⱦɚлɟɟжиɜоɬномɭɜнɭɬɪиɛɪюшинно [8] ɜɜоɞилиɫлɟɞɭɟмоɟɜɟщɟɫɬɜо 0,9% ɪɚɫɬɜоɪɟнɚɬɪия 10 ɭɫɬɚноɜлɟнɚэкɫпɟɪимɟнɬɚльпɪоɜɟɞɟнииɞополниɬɟльныɯɞоɜɚнийɎɚɪмɚɬɟɫɬɪɚмкɚɯпɪоɜɟɞɟэкɫпɟɪɬизыоɛъɟкɬɚɜключɚɜшɟɝоиɫɫлɟɞɭɟмоɟɜɟщɟɫɬɜоПоɫлɟпɪиёмɚɜɟщɟɫɬɜɚжиɜоɬноɟпомɟщɚлоɫьмɟɬɚɛоличɟɫкɭюкɚмɟɪɭ 24 чɚɫɚɫɛоɪɚпоɫɬэкɫпɟɪимɟнɬɚльнойɛиожиɞкоɫɬикоɬопɪоɜоɞилɫяɟɝомɟɬɚɛолиɬоɜɫоɝлɚɫномɟɬоɞикɚмопиɫɚннымнижɟОɛоɪɭɞоɜɚниɟпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚȼыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚȼЭЖɏпɪоɜɟɞɟнияэкɫпɟɪимɟнɬɚиɫпользоɜɚноɫлɟɞɭющɟɟоɛоɪɭɞоɜɚниɟжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮɮиɪмы ?Shimadzu LCMC-8050? комплɟкɫɟмɚɫɫɫɟлɟкɬиɜнымɞɟɬɟкɬоɪомɌипɬоɪɚ ? ɬɪойнойкɜɚɞɪɭпольɞɜойнымиɫɬочникомɯимичɟɫкɚяɚɬмоɫɮɟɪномɞɚɜлɟнииэлɟкɬɪоɫпɪɟйɊɚзɞɟлɟниɟɜɟщɟɫɬɜиɫɯоɞилоɯɪомɚɬоɝɪɚɮичɟɫкойколонкɟмɚɬɟɪиɚл ? нɟɪжɚɜɟющɚяɫɬɚльɯɚɪɚкɬɟɪиɫɬики ? 150 * 3,0 ɋоɪɛɟнɬ ? ȽɚзоɜɚяɯɪомɚɬоɝɪɚɮияȽɚзоɜыймɚɬоɝɪɚɮ ?Agilent 7890A? мɚɫɫɫпɟкɬɪомɟɬɪомколонкɚ 103 нɟполяɪнɚя HP-5ms 28 ? 0,25 кɚчɟɫɬɜɟноɫиɬɟляиɫпользɭɟɬɫяɝɟлийкоɬоɪыйпоɞɚёɬɫяɫкоɪоɫɬью 1,2 ɪɚɛоɬы ? split/splitless, поɬокɚ ? 1:10, зɚɞɟɪжкɚɜключɟния ? поɫлɟɜɜоɞɚ 1 минɭɬɚɌɟмпɟɪɚɬɭɪɚинɬɟɪɮɟйɫɚ 280?ɬɟмпɟɪɚɬɭɪɚинжɟкɬоɪɚ 250?пɪоɝɪɚммиɪɭɟмɚяɬɟмпɟɪɚɬɭɪɚколонки ? Ɋɟжимɪɚɛоɬыɞɟɬɟкɬоɪɚɫɟлɟкɬиɜныймониɬоɪинɝинɬɟɪɜɚл ? 9?13 нɚпɪяжɟниɟɭмножиɬɟлɟɜɟличиныɚɜɬомɚɬичɟɫкойнɚɫɬɪойкиПоɞɝоɬоɜкɚоɛъɟкɬоɜиɫɫлɟɞоɜɚнияПɪиɝоɬоɜлɟниɟɫɬɚнɞɚɪɬноɝоɪɚɫɬɜоɪɚпоɞɛоɪɚɜыɯоɞɚɜɟщɟɫɬɜɚэкɫпɟɪимɟнɬɚльномоɛоɪɭɞоɜɚниипɪиɝоɬоɜлɟнɫɬɚнɞɚɪɬныйɪɚɫɬɜоɪɜɟщɟɫɬɜɚ THJ-2201 ɚцɟɬониɬɪилɟконцɟнɬɪɚции 1 Ⱦɚлɟɟ 0,5 полɭчɟнноɝоɪɚɫɬɜоɪɚпомɟщɚлоɫьɯɪомɚɬоɝɪɚɮичɟɫкɭюɜиɚлкɭɪɚɫɬɜоɪɚɜɜоɞилиинжɟкɬоɪɯɪомɚɬоПɪоɛопоɞɝоɬоɜкɚȼЭЖɏпɪоɛиɪкɭзɚɜинчиɜɚющɟйɫякɪышкойɜмɟɫɬимоɫɬью 10 ɜноɫили 3 ɚнɚлизиɪɭɟмоймочиɞоɛɚɜляли 0,5 ɪɚɫɬɜоɪɚ NaOH ɜыɞɟɪжиɜɚли 2 чиɫɬɭюɫɭɯɭюпɪоɛиɪкɭоɛъёмом 10 3 ɝиɞɪолизɚɬɚмочиȽиɞɪолизɚɬпоɞкиɫляли pH 2?3 ɞоɛɚɜлɟниɟм 250?350 концɟнɬɪиɪоɜɚннойɫолянойкиɫлоɬыпɪоɛиɪкɭɜноɫили 3 ɫмɟɫиизоокɬɚнэɬилɚцɟɬɚɬ (7:1). Помɟщɚли 10 оɪɛиɬɚльныйшɟйкɟɪЦɟнɬɪиɮɭɝиɪоɜɚли 5 3000 ОɬɞɟляличɟɫкийпɟɪɟноɫилипɪоɛиɪкɭɭпɚɪиɜɚнияɭпɚɪиɜɚлиɬокɟɝоɪячɟɝоɜозɞɭɯɚэкɫɬɪɚкɬɭɞоɛɚɜлялиɚцɟɬониɬɪилɚɜɫɬɪяɯиɜɚлиɜиɛɪомикɫɟɪɟɫɟкɚнɚлизиɪоɜɚлиɍɫлоɜияɯɪомɚɬоɝɪɚɮиɪоɜɚнияȼЭЖɏ?10 L/min, Interface Temperature ? 300?, DL Tempera-, Heat Block Temperature ? 400?emperature ? 400?Ɋɟɝиɫɬɪɚциюоɛɪɚɛоɬкɭɯɪомɚɬоɝɪɚɮичɟɫкойинɮоɪмɚцииоɫɭщɟɫɬɜлялипомощьюоɛɟɫпɟчɟния LCsolution (ver. 1.25) [10].Пɪоɛопоɞɝоɬоɜкɚɞɟɪиɜɚɬизɚцияɮлɚконпомɟщɚли 2 мочипɪиɛɚɜляли 150 50% ɪɚɫɬɜоɪɚ NaOH пɟɪɟмɟшиɜɚлиɎлɚконплоɬноɭкɭпоɪиɜɚлипомɟщɚлиɬɟɪмоɛлок 10 60?Поɫлɟоɯлɚжɞɟнияɮлɚконɜɫкɪыɜɚɞоɛɚɜлялиɫɬɚнɞɚɪɬɝɟкɫɟнɚлɚ 100 0,2 пɪиɛɚɜлялиɪɚɫɬɜоɪ HCl pH 2?3 экɫɬɪɚɝиɪоɜɚлиɫмɟɫьюɝɟкɫɚнэɬилɚцɟɬɚɬ (7:1) 5 оɬɞɟлялиɜыпɚɪиɜɚлиɫɭɯоɝооɫɬɚɬɬокɟɬёплоɝоɜозɞɭɯɚ (40?ɫɭɯомɭоɫɬɚɬкɭпɪиɛɚɜляли 500 ɛɟзɜоɞноɝоɚцɟɬонɚɞиɫɬоɝо 2 кɚɪɛонɚɬɚкɚлияɝɟɪмɟɬичнозɚкɪыɜɚлинɚɝɪɟɜɚли 60?ɬɟчɟнии 60 ɬɟɪмоɛлокɟɎлɚконоɯлɚжɞɚлиɊɚɫɬɜоɪпɟɪɟноɫиɮлɚконɜыпɚɪиɜɚлиɬокɟɚзоɬɚɋɭɯойоɫɬɚɬокɞɟɪиɜɚɬизиɪоɜɚнноɝоɪɚɫɬɜоɪялиэɬилɚцɟɬɚɬɚ 1?2 ɜɜоɞилиинжɟкɬоɪɯɪомɚɬомɚɫɫɫпɟкɬɪомɟɬɪɚ [11].Ɋɟɝиɫɬɪɚциюоɛɪɚɛоɬкɭɯɪомɚɬоɝɪɚɮичɟɫкойинɮоɪмɚцииоɫɭщɟɫɬɜлялипомощьюноɝооɛɟɫпɟчɟния AMDIS GC/MS Analysis (ver. 2.66) . 2.66) Ɋɟзɭльɬɚɬыɪɟзɭльɬɚɬɟпɪоɞɟлɚннойɪɚɛоɬыполɭчɟныɫлɟɞɭющиɟпоɞɬɜɟɪжɞɚюɝипоɬɟзɭɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯпоɫлɟпɪиёмɚɜɟщɟɫɬɜɚ THJ-2201 чɟлоɜɟкɚжиɜоɬноɝоȺнɚлизɫɬɚнɞɚɪɬноɝопɪоɜоɞилɫямɟɬоɞɚ MRM-пɟɪɟɯоɞоɜPrecursor ? 233.30, Collision energy ? 15. ɏɪомɚɬоɝɪɚммɚɫɬɚнɞɚɪɬноɝоɪɚɫɬɜоɪɚпɪɟɞɫɬɚɜлɟнɚɫɭнкɟɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryɊиɫɭнокɋɬɚнɞɚɪɬныйɪɚɫɬɜоɪɊиɫɭнокɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪноɝожиɜоɬноɝопɟɪɟɯоɞоɜɊиɫɭнокɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪноɝожиɜоɬноɝопɟɪɟɯоɞоɜPharmacy & Pharmacology V. 5 N 4, 2017Иɫɫлɟɞоɜɚниɟɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪныɯжиɜоɬныɯȼыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоиɫɫлɟɞоɜɚнииɛиожиɞкоɫɬижиɜоɬноиɫпользоɜɚлимɟɬоɞɫоɛɫɬɜɟннымконɬɪолɟммочɭɫоɛиɪɚлиɞɜɚжɞы ? поɫлɟɜɜɟɞɟнияɜɟщɟɫɬɜɚɫооɬɜɟɬɫɬɜɟнноɚнɚлизɚиɫпользоɜɚлɫямɟɬоɞ MRM-пɟɪɟɯоɞоɜнɚɬиɜноɝоɜɟщɟɫɬɜɚɯɚɪɚкɬɟɪныпɚɪɚмɟɬɪы: Product ion ? 361.40, Precursor ? 233.30, Collision Energy ? 15.0. мɟɬɚɛолиɬɚɯɚɪɚкɬɟɪныɫлɟɞɭющиɟпɚɪɚмɟɬɪы: Product ion ? 373.20, Precursor ? 155.20, Collision Energy ? 15.0. полɭчɟнныɯɫлɟɞɭɟɬчɬоконɬɪольɊиɫɭнокМɚɫɫɫпɟкɬɪпикɚɯɚɪɚкɬɟɪноɝоɜɟщɟɫɬɜɚɋɜɟɪɯɭэкɫпɟɪимɟнɬɚльныйлɚɛоɪɚɬоɪноɟжиɜоɬноɟɫнизɭɛиɛлиоɬɟчныйчɟлоɜɟкɊиɫɭнокМɚɫɫɫпɟкɬɪпикɚɯɚɪɚкɬɟɪноɝомɟɬɚɛолиɬɚɜɟщɟɫɬɜɚɋɜɟɪɯɭэкɫпɟɪимɟнɬɚльныйлɚɛоɪɚɬоɪноɟжиɜоɬноɟɫнизɭɛиɛлиоɬɟчныйчɟлоɜɟкмочɟɞɚнноɝо MRM-пɟɪɟɯоɞɚɯɪомɚɬоɝɪɚɮиɪоɜɚниимɚкɫимɚльнɚяинɬɟнɫиɜноɫɬьпикоɜ ? 720 ɬоɝɞɚкɚкɯɪомɚɬоɝɪɚммɟɛиожиɞкоɫɬипоɫлɟпɪиёмɚɜɟщɟɫɬɜɚоɬчёɬлиɜонɚɬиɜноɝоɜɟщɟɫɬɜɚɬɚкжɟиɫкомоɝомɟɬɚɛолиɬɚоɬɜɟɬɫɬɜɭющиɯкɚжɞыйɫɜоɟмɭ MRM ? пɟɪɟɯоɞɭмɚкɫимɚльнɚяинɬɟнɫиɜноɫɬь ? 1 425 000 мɚɬоɝɪɚммыиɫɫлɟɞɭɟмыɯɛиолоɝичɟɫкойжиɞкоɫɬилɚɛоɪɚɬоɪныɯжиɜоɬныɯпоɫлɟɜɟщɟɫɬɜɚ THJ-2201 пɪɟɞɫɬɚɜлɟныɪиɫɭнкɚɯ 3 ɫооɬɜɟɬɫɬɜɟнноȽɚзоɜɚяɯɪомɚɬоɝɪɚɮиямочɟлɚɛоɪɚɬоɪноɝожиɜоɬноɝопоɫлɟпɪиёмɚɜɟщɟɫɬɜɚɪɭжɟныɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryмɟɬɚɛолиɬоɜноɜоɝоɫинɬɟɬичɟɫкоɝокɚннɚɛиноиɞɚчɟлоɜɟкɚлɚɛоɪɚɬоɪнойяɜлɟноɭɫɬɚноɜлɟноɫɭщɟɫɬɜɟнноɟɫɯоɞɫɬɜомɚкɫимɚльнойинɬɟнɫиɜноɫɬьюɬɚɛоличɟɫкиɯпɚɪɚмɟɬɪыɞɟɬɟкɬиɪоɜɚниямɟɬɚɛолиɬоɜɯɪомɚɬоɝɪɚɮиɪоɜɚнияЗɚключɟниɟɍчиɬыɜɚяполɭчɟнныɟɪɟзɭльɬɚɬыэкɫпɟɪимɟнɬɚможноɫɞɟлɚɬьɜыɜоɞпɪиɝоɞноɫɬипɪɟɞложɟннойкомплɟкɫноймɟɬоɞикиɚнɚлизɚоɫнɚщённоɫɬилɚɛоɪɚɬоɪиинɚлилɚɛоɪɚɬоɪныɯжиɜоɬныɯɪɚзноɜиɞноɫɬьɯɪомɚɬоɝɪɚɮичɟɫкоɝооɛоɪɭɞоɜɚнияɌɚкжɟɭчёɬомɜыполнɟнныɯиɫɫлɟɞоɜɚний [13, 14] можноɫɞɟлɚɬьɜыɜоɞзнɚчиɬɟльноймɟжɜиɞоɜойɫɯожɟɫɬимɟɬɚɛоличɟɫкиɯчɟлоɜɟкɚлɚɛоɪɚɬоɪнойɜɟщɟɫɬɜɯимичɟɫкиɫɯоɞныɯиɫɫлɟɞɭɟмымɬочкиɚɜɬоɪоɜиɫɫлɟɞоɜɚниɟяɜляɟɬɫяпɟɪɫпɟкɬиɜнымɬɚккɚкɜнɟɞɪɟнииэкɫпɟɪɬнɭюпɪɚкɬикɭможɟɬɫɭщɟɫɬɜɟнноɫокɪɚɬиɬьɫɟнияноɜоɝопɫиɯоɚкɬиɜноɝоɜɟщɟɫɬɜɚпɟɪɟчɟньзɚпɪɟщённыɯ I позɜоляяполɭчɚɬьмоɞɟльмɟɬɚɛолизмɚиɫɫлɟɞɭɟмоɝоɜɟщɟɫɬɜɚɛɟзɫɭɛъɟкɬɚоɬɪɚɜлɟнияоɫноɜɟɛиожиɞкоɫɬɟйлɚɛоɪɚɬоɪныɯжиɜоɬныɯɪɚкɬɟɪныɟнɚɬиɜноɝоɜɟщɟɫɬɜɚоɞноɝомɟɬɚɛолиɬоɜɜɟщɟɫɬɜɚ THJ-2201 мɚɫɫɫпɟкɬɪɚмимɚɫɫɫпɟкɬɪɚмичɟлоɜɟчɟɫкиɯпɪоɝɪɚммноɝокомплɟкɫɚ AMDIS GC/MS Analysis (ver. 2.66.). ɫпɟкɬɪыиɫɫлɟɞоɜɚнноɝонɚɬиɜноɝоɫоɟɞинɟнияɟɝомɟɬɚɛолиɬɚпɪɟɞɫɬɚɜлɟнычɟлоɜɟчɟɫкимизɭльɬɚɬɚмиɪиɫɭнкɚɯɫооɬɜɟɬɫɬɜɟнноОɛɫɭжɞɟниɟполɭчɟнныɯможноɫɞɟлɚɬьɫлɟɞɭющиɟɜыɜоɞыȼЭЖɏɜыɯоɞɚɜɟщɟɫɬɜɚɫɬɚнɞɚɪɬномзɚɞɚнном MRM-пɟɪɟɯоɞɟɫооɬɜɟɬɫɬɜɭɟɬɜыɯоɞɚнɚɬиɜноɝоɜɟщɟɫɬɜɚэкɫпɟɪимɟнɬɚльномчɬоɫɜиɞɟɬɟльɫɬɜɭɟɬɬомчɬоɜыɫокойɞолɟйɜɟɪояɬноɫɬи ? эɬооɞноɜɟщɟɫɬɜоɯɪомɚɬоɝɪɚммконɬɪольноймочипоɫɬэкɫпɟɪимɟнɬɚльнойможноɫɞɟлɚɬьɜыɜоɞчɬоникɚкиɯэнɞоɝɟнныɯɜɟщɟɫɬɜɫооɬɜɟɬɫɬɜɭющиɯпɪɟɞложɟннымпɟɪɟɯоɞɚмɪɭжɟноɯɪомɚɬоɝɪɚммɟпоɫɬэкɫпɟɪимɟнɬɚльноймочиоɬчёɬлиɜонɚɬиɜноɝоɜɟщɟɫɬɜɚ THJ-ɟɝомɟɬɚɛолиɬɚɫооɬɜɟɬɫɬɜɭющиɟпɪɟɞложɟннымпɟɪɟɯоɞɚмкɚчɟɫɬɜɟнныɯоɬличийɫоɫɬɚɜɚмиIntroduction. One of the most acute problems faced cking of new psychoactive sub-stances. Around the world, the number of substances used for recreational purposes is growing. Unfortunately, Rus-sia has not become an exception, scores of new substances used for the purpose of stupefying have been distributed on its territory. Each government struggles with this prob-lem in its own way, which is connected with the peculiari-ties of the legislation in the sphere of restriction of narcotic drugs turnover. Of course, in our country, the ght against cking of intoxicating substances is actively conducted, but it often takes a fairly long time to pass since bition against its synthesis, production, etc. through the A group of scientists at Perm State Pharmaceutical group of scientists at Perm State Pharmaceutical of the turnover of new psychoactive substances is possi-ble through reference to ?analogues of narcotic drugs and psychotropic substances?, the de? nition of which is giv-en in Federal Law No. 3-FZ of 08.01.1998. This group cking in the Rus-the psychoactive effect which they produce.substances.? The results of the research were repeatedly and pharmacological parts. The ?Methodological Rec-used. However, the objects of expert research conducted uids, which To identify the fact of using prohibited substances and, subsequently, to determine the speci c structure Pharmacy & Pharmacology V. 5 N 4, 2017 uoropentyl) -1H-indazole, known under the trivial name of THJ-2201 or AM(N)-2201. Another psychoactive substance known as JWH-018 (IUPAC: ?progenitor? of the test substance. The difference be-indole one [4]. The structural formula of the test sub- uoropentyl)-1H-indazole (THJ-2201)peripheral CB2 receptors [5]. After taking the substance, the following effects are observed: evident sedation, ne and gross motor skills of smooth culty in orientation in space, lowering culty in orientation in space, lowering The aim of this study is to work out a procedure for the determination of the test substance THJ-2201 and its is also the goal of this work. For a relatively rapid perfor- les and and In the proposed study, some methodological recom-of the new synthetic cannabimimetic THJ-2201 in the bi- uid (urine) of laboratory rats are presented for A sam-ment agencies of the Ministry of Internal Affairs of the nity the The experiments were carried out on white mature males of laboratory rats in the Wis-Pharmaceutical Academy in a separate room, at the air The diet was standard for laboratory animals (GOST R for preclinical research in the Russian Federation (GOST To obtain a control uid in the same animal, which rm for 24 hours, with unlimited uid urine control. After that, the animal was placed into a After that, the animal was placed into a with the test substance (0.9% solution of sodium chloride at a dose of 10 mg / kg (the dose was established ex-perimentally while carrying out additional studies on the basis of the ?Pharmatest? as a part of expert evaluation of the object including the test substance). After taking the tal bio-liquid, in which the search for THJ-2201 and its described below.High performance liquid chromatography To carry out the experiment the following rm ?Shimadzu LCMC-8050? in combination with a mass-selective detector. The detector type is a triple graphic column (the material is stainless steel, the char-Gas chromatography (GC). Gas chromatograph ?Agilent 7890A? with Agilent 5975C mass spectrometer, ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological Chemistry ux division was 1:10, the on-delay was 1 minute after the sample insertion. The interface tempera-3-280-10-300. The detector operation mode was selec-voltage on the multiplier was 200 V higher than the auto Preparation of a standard solution. To determine the experimental equipment, a standard solution of THJ-prepared. Further, 0.5 ml of the resulting solution was was injected into the chromatograph injector.Sample preparation for HPLC-MS. 3 ml of the ed up to pH 2-3 by adding 3 ml of isooctane-ethyl acetate (7: 1) was placed into the test tube. Then the test tube was placed on the orbital shaker for 10 minutes, centrifuged for 5 minutes at 3000 rpm. The organic layer was separated, transferred to the glass evaporation tube and evaporated in the stream of hot air. 500 l of acetonitrile was added to the extract, shaken Chromatography conditions for HPLC-MS. Neb-10 L/min, Interface Temperature was 300?, DL Tem-, Heat Block Temperature was 400?emperature was 400?cessing of chromatographic information was carried out using LC solution software (ver 1.25) [10].Sample preparation and derivatization for GC- 2 ml of urine was placed into the vial, 150 NaOH solution was added and mixed. The bottle was 60?C. After cooling the vial was opened, a hexenal stan-n-hexane-ethyl acetate (7 : 1) in a 5 ml portion. The top for 60 minutes in a fuser. The bottle was cooled. The a stream of nitrogen. The dry residue of the derivatized ter injector [11].formation was carried out using the AMDIS GC / MS Analysis software (ver.2.66) [12]. rming the hypothesis of the sim- les after administration of THJ-361.40, precursor was 233.30, collision energy was 15. uid of laboratory animals.High performance liquid chromatography. In uidity of the animal, a comparison the substance (Figure 4 and Figure 3, respectively). The MRM-transitions method was used for the analysis. The lision energy is 15.0. The following parameters are typi-155.20, collision energy is 15.0. From the data obtained it follows that in the ?control matography were found out (the maximum intensity of the peaks was 720 units), whereas on the chromatogram of uid collected after taking the substance, the peak of the native substance was clearly visible, as well as the peak of the desired metabolite, corresponding to each of its MRM-transitions (the maximum intensity was 1,425,000 uid of laboratory animals before and after taking THJ-2201 are shown in Figures 3 and 4, respectively.Gas chromatography. In the urine of a laborato-of the THJ-2201 substance with mass spectra coincid-the database of the AMDIS GC / MS Analysis software package (ver. 2.66.). The mass spectra of the sample for respectively.We can draw the following conclusions the peaks of the native substance THJ-2201 and its Pharmacy & Pharmacology V. 5 N 4, 2017Figure 2 ? Standard solution THJ-2201. MRM analysisFigure 3 ? A sample of the biological uid of a laboratory animal before taking THJ-2201. MRM Transition MethodFigure 4 ? A sample of the biological uid of a laboratory animal after taking THJ-2201. MRM Transition MethodɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryFigure 5 ? Mass spectrum of the peak, characteristic for the native substance THJ-2201. Above ? experimental (laboratory animal), below ? library (man)Figure 6 ? Mass spectrum of the peak, characteristic for the metabolite of substance THJ-2201. Above ? no qualitative differences between the ionic composi-noid THJ-2201 in humans and in laboratory rats have tensity in different metabolic pro les was established;Taking into account the obtained results Taking into account the previous studies [13, 14], cant degree of les and laboratory rats? for substances chemically similar to the From the point of view of the authors, the study is cantly reduce the time of in-troducing a new psychoactive substance into the list of prohibited substances (List I of the National Assembly and the Law), making it possible to obtain a model of metabolism of the test substance without a poisoning uids of laboratory an-Pharmacy & Pharmacology V. 5 N 4, 2017ȻиɛлиоɝɪɚɮичɟɫкийɎɟɞɟɪɚльныйзɚконянɜɚɪянɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜɚɯпɫиɯоɬɪопныɯɜɟщɟɫɬɜɚɯПоɫɬɚноɜлɟниɟПɪɚɜиɬɟльɫɬɜɚ 30 1998 681 ?ɭɬɜɟɪжɞɟниипɟɪɟчнянɚɪкоɬичɟɫкиɯɫɪɟɞɫɬɜпɫиɯоɬɪопныɯɜɟщɟɫɬɜпɪɟкɭɪɫоɪоɜпоɞлɟжɚщиɯконɬɪолюɊоɫɫийɫкойɎɟɞɟɪɚцииɌɟмɟɪɞɚшɟɜКиɫɟлёɜɚКолычɟɜКɚльницкийȼЭЖɏ - ОПɊȿȾȿЛȿНИȿНȿКОɌОɊЫɏНȺɊКОɌИЧȿɋКИɏПɊИɊОȾНОȽОɋИНɌȿɌИЧȿɋКОȽОПɊОИɋɏОЖȾȿ ? ПɊОИЗȼОȾНЫɏ N-ИНȾОЛИЛКȿɌОНОȼȺМИНОȺɊИЛКȿɌОНОȼКИɋЛОɌɌɊОПȺНОȼЫɏ // ȺнɚлиɬикɚконɬɪольɋоɫноɜȻɭлыɝинɚОɋНОȼНЫȿɏȺɊȺКɌȿɊИɋɌИКИНОȼОȽОɋИНɌȿɌИЧȿɋКОȽОНȺɎɌȺЛИНИНȾȺЗОЛМȿɌȺНОН THJ-2201 // НɚɪколоɝияCornelius H., Schoeder C.T., Pillaiyar T., Burkhard M., M?ller C.E. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS IDENTIFIED AS CONSTITUENTS OF SPICE // Forensic Toxicology34 (2). P. 329?343.10.1007/s11419-016-0320-2THJ-2201 // psychonautwiki.org URL: https://psychonautwiki.org/wiki/THJ-2201.METABOLIC CAGE // http://www.openscience.ru URL: http://www.openscience.ru/index.ɊɭкоɜоɞɫɬɜопɪоɜɟɞɟниюɞоклиничɟɫкиɯиɫɫлɟɞоɜɚнийлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜȽɪиɮИнɮоɪмɚционноɟɪɭжɟниɟɫинɬɟɬичɟɫкиɯкɚннɚɛимимɟɬикоɜнɚɪкоɬичɟɫкиɯпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜмɟɬɚɛолиɬоɜмочɟɜолоɫɚɯноɝɬяɯмɟɬоɞɚмижиɞкоɫɬнойɯɪомɚɬоɝɪɚɮиимɚɫɫɫпɟкɬɪомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмМиниɫɬɟɪɫɬɜоЗɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииНɚционɚльныйнɚɭчныйцɟнɬɪнɚɪколоɝииLCsolution Software // www.ssi.shimadzu.com URL: http://www.ssi.shimadzu.com/products/product.cfm?pro-КɚɬɚɟɜМɟлɟнɬьɟɜȾɜоɪɫкɚяМȿɌȺȻОЛИɌОȼМОЧȿȻɭɬлɟɪоɜɫкиɟɫооɛщɟния. 2013. Vol. 36. No. 10. P. 29?36.Мɚлкоɜɚɏɚɪɚкɬɟɪиɫɬикɚмɟɬɚɛолизмɚɪɚзɪɚɛоɬкɚмɟɬоɞикиɫинɬɟɬичɟɫкоɝокɚннɚɛиноиɞɚ pb-22 мочɟлɚɛоɪɚɬоɪныɯжиɜоɬныɯ // ȾоɫɬижɟнияпɪоɛлɟмынɚɭкиНɚɭчныйжɭɪнɚлМɚлкоɜɚɏȺɊȺКɌȿɊИɋɌИКȺМȿɌȺȻОЛИЗМȺɊȺЗɊȺȻОɌКȺМȿɌОȾИКИОПɊȿȾȿЛȿНИЯɋИНɌȿɌИЧȿɋКОȽО AB-PINACA МОЧȿЛȺȻОɊȺɌОɊНЫɏЗɞоɪоɜьɟоɛɪɚзоɜɚниɟɜɟкɟ. 2016. Vol. 18. No. 10. . 113?124.Referencesencesstvah i psihotropnyh veshchestvah? [?On Narcotic Drugs and Psychotropic Substances?]. (In Russ.)2. Postanovlenie Pravitelstva RF ot 30 iyunya 1998 g N 681 [Resolution of the Government of the Russian Feder--psychotropic substances and their precursors subject to control in the Russian Federation?]. (In Russ.)3. Temerdashev A.Z., Kiseleva N.V., Kolychev I.A., Kalnitsky A.G. GH-MS I VEZHKH-MS - OPREDELENIE NE-KOTORYH NARKOTICHESKIH SREDSTV PRIRODNOGO I SINTETICHESKOGO PROISKHOZHDENI-YA - PROIZVODNYH N-ALKIL-3-INDOLILKETONOV -AMINOARILKETONOV P-AMINOBENZOJNYH KISLOT KANNABINOIDOV I TROPANOVYH ALKALOIDOV [GC-MS AND HPLC-MS - DETERMINA-TION OF SOME DRUGS OF NATURAL AND SYNTHETIC ORIGIN - DERIVATIVES OF N-ALKYL-3-IN-DOLYLKETONS, -AMINOARYLCRETHONES, P-AMINOBENZOIC ACIDS, CANNABINOIDS AND TROPANIC ALKALOIDS]. Analitika i contrololAnalytics and Control]. 2012. N 3. P. 240?247. (In Russ.)Vasiliev AB, Sosnov DA, Bulygina I.E. IDENTIFIKACIYA I OSNOVNYE HARAKTERISTIKI NOVOGO SINTETICHESKOGO KANNABINOIDA NAFTALIN-1-IL 1-PENTIL-1N-INDAZOL-3-IL METANON THJ-2201 [IDENTIFICATION AND MAIN CHARACTERISTICS OF NEW SYNTHETIC CANNABINOID (NAPHTHALIN-1-IL) (1-PENTIL-1H-INDAZOL-3-IL) METHANON THJ-2201]. Nakrologiya [Nakropologi- 2014. No. 5 (149). P. 79?82. (In Russ.)Cornelius H., Schoeder C.T., Pillaiyar T., Burkhard M., M?ller C.E. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS IDENTIFIED AS CONSTITUENTS OF SPICE. Forensic Toxicology. 2016. 34 (2). P. 329-343. DOI: 10.1007 / s11419-016-0320-2.THJ-2201. psychonautwiki.org URL: https://psychonautwiki.org/wiki/THJ-2201.METABOLIC CAGE. http://www.openscience.ru URL: http://www.openscience.ru/index.ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬокɫиколоɝичɟɫкɚяPharmaceutical and Toxicological ChemistryMironov A.N. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [A guide to con- guide to con-Мoscow: Grif and To], 2012. 751 p. (In Russ.) i s mass-spektrometricheskim de-i s mass-spektrometricheskim de-and their metabolites in urine, hair and nails by liquid chromatography with mass spectrometric detection?]. Ministerstvo Zdravoohraneniya Rossijskoj Federacii Nacionalnyj nauchnyj centr narkologii [Ministry of Health of the Russian Federation, National Scienti? c Center of Narcology]. 2014. (In Russ.)LCsolution Software. www.ssi.shimadzu.com URL: http://www.ssi.shimadzu.com/products/product.cfm?pro-Kataev S.S., Melentiev A.B., Dvorskaya O.N. IDENTIFIKACIYA METABOLITOV KANNABIMIMETIKA PB-22 V MOCHE [IDENTIFICATION OF METABOLITES OF PB-22 CANNABYMETHYME IN URINE]. Butlerovskie soobshcheniyaovskie soobshcheniyaButlerov Communications]. 2013. Vol. 36. No. 10. P. 29?36. (In Russ.)Apushkin D.Yu., Andreev A.I., Malkova T.L. Harakteristika metabolizma i razrabotka metodiki opredeleniya .L. Harakteristika metabolizma i razrabotka metodiki opredeleniya opment of a technique for the determination of synthetic cannabinoid pb-22 in urine of laboratory animals]. Dos-tizheniya i problemy sovremennoj nauki [Achievements and problems of modern science]. SPb Nauchnyj zhurnal Globus [SPb.: Scienti? c journal ??Globus??]. 2016. P. 102?107. (In Russ.)Apushkin D.Yu., Malkova T.L. Harakteristika metabolizma i razrabotka metodiki opredeleniya sinteticheskogo .L. Harakteristika metabolizma i razrabotka metodiki opredeleniya sinteticheskogo method of determining ab-pinaca synthetic cannabinoid in uroline of laboratory animals]. Zdorove i obrazovanie ove i obrazovanie . 2016. Vol. 18. No. 10. P. 113?124. (In Russ.)КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜȺɜɬоɪы ? млɚɞшийнɚɭчныйɫоɬɪɭɞникнɚɭчноɝооɬɞɟлɚПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟнɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɪɚзɪɚɛоɬкɚмɟɬоɞикопɪɟɞɟлɟнияпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜɛиолоɝичɟɫкиɯжиɞкоɫɬяɯɜыɫокоэɮɮɟкɬиɜнɚяжиɞкоɫɬнɚяɯɪомɚɬоɝɪɚɮияɝɚзоɜɚяɯɪомɚɬоɝɪɚɮияɯɟмоинɮоɪмɚɬикɚмолɟкɭмоɞɟлиɪоɜɚниɟМɚлкоɜɚɌɚмɚɪɚЛɟониɞоɜнɚ ? ɞокɬоɪɮɚɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪзɚɜɟɞɭющийкɚɮɟɞɪойɬокɫиколоɝичɟɫкойПɟɪмɫкɚяɝоɫɭɞɚɪɫɬɜɟнɮɚɪмɚцɟɜɬичɟɫкɚяɚкɚɞɟмияОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɪɚзɪɚɛоɬкɚɫоɜɟɪшɟнɫɬɜоɜɚниɟмɟɬоопɪɟɞɟлɟниялɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɬомчиɫлɟɬокɫиколоɝичɟɫкоɟзнɚчɟниɟиɫɫлɟɞоɜɚниɟпɫиɯоɚкɬиɜныɯɜɟщɟɫɬɜоɛɟɫпɟчɟниɟкɚчɟɫɬɜɚɚнɚлиɬичɟɫкиɯиɫɫлɟɞоɜɚнийПоɫɬɭпилɚɪɟɞɚкциюПɪиняɬɚпɟчɚɬи ict of interest ict of interest.Apushkin Danila Yurievich junior research as- c department, Perm State Pharma-ceutical Academy. Research interests: working out the uids, high-performance liquid chromatogra-phy, gas chromatography, chemoinformatics, molecular Malkova Tamara Leonidovna Doctor of Sciences (Pharmacy), Professor, Head of the Department of Toxi-cological Chemistry, Perm State Pharmaceutical Acade-my. Research interests: working out thedetermination of medicinal products, including those of cance, the study of new psychoactive
×

About the authors

D. Yu. Apushkin

Perm State Pharmaceutical Academy

Email: apushkinjob@gmail.com

T. L. Malkova

Perm State Pharmaceutical Academy

Email: kaftox@mail.ru

References

  1. Федеральный закон от 8 января 1998 г. № 3-ФЗ «О наркотических средствах и психотропных веществах».
  2. Постановление Правительства РФ от 30 июня 1998 г. № 681 «Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации».
  3. Темердашев А.З., Киселёва Н.В., Колычев И.А., Кальницкий А.Г. ГХ-МС И ВЭЖХ-МС ОПРЕДЕЛЕНИЕ НЕКОТОРЫХ НАРКОТИЧЕСКИХ СРЕДСТВ ПРИРОДНОГО И СИНТЕТИЧЕСКОГО ПРОИСХОЖДЕНИЯ – ПРОИЗВОДНЫХ N-АЛКИЛ-3-ИНДОЛИЛКЕТОНОВ, ɑ-АМИНОАРИЛКЕТОНОВ, П-АМИНОБЕНЗОЙНЫХ КИСЛОТ, КАННАБИНОИДОВ И ТРОПАНОВЫХ АЛКАЛОИДОВ // Аналитика и контроль. 2012. №3. С. 240–247.
  4. Васильев А.Б., Соснов Д.А., Булыгина И.Е. ИДЕНТИФИКАЦИЯ И ОСНОВНЫЕ ХАРАКТЕРИСТИКИ НОВОГО СИНТЕТИЧЕСКОГО КАННАБИНОИДА (НАФТАЛИН-1-ИЛ)(1-ПЕНТИЛ-1Н-ИНДАЗОЛ-3-ИЛ) МЕТАНОН THJ-2201 // Наркология. 2014. №5 (149). С. 79–82.
  5. Cornelius H., Schoeder C.T., Pillaiyar T., Burkhard M., Müller C.E. PHARMACOLOGICAL EVALUATION OF SYNTHETIC CANNABINOIDS IDENTIFIED AS CONSTITUENTS OF SPICE // Forensic Toxicology. 2016. 34 (2). P. 329–343. doi: 10.1007/s11419-016-0320-2
  6. THJ-2201 // psychonautwiki.org URL: https://psychonautwiki.org/wiki/THJ-2201.
  7. METABOLIC CAGE // http://www.openscience.ru URL:http://www.openscience.ru/index.php?page=other&item=018
  8. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2012. 751 c.
  9. Информационное письмо «Обнаружение синтетических каннабимиметиков, наркотических, психоактивных веществ и их метаболитов в моче, волосах и ногтях методами жидкостной хроматографии с масс-спектрометрическим детектированием» // Министерство Здравоохранения Российской Федерации, Национальный научный центр наркологии. 2014 г.
  10. LCsolution Software // www.ssi.shimadzu.com URL: http://www.ssi.shimadzu.com/products/product.cfm?product=lcsolution.
  11. Катаев С.С., Мелентьев А.Б., Дворская О.Н. ИДЕНТИФИКАЦИЯ МЕТАБОЛИТОВ КАННАБИМИМЕТИКА PB-22 В МОЧЕ // Бутлеровские сообщения. 2013. Vol. 36. No. 10. P. 29–36.
  12. AMDIS // chemdata.nist.gov URL: http://chemdata.nist.gov/dokuwiki/doku.php?id=chemdata:amdis.
  13. Апушкин Д.Ю., Андреев А.И., Малкова Т.Л. Характеристика метаболизма и разработка методики определения синтетического каннабиноида pb-22 в моче лабораторных животных // Достижения и проблемы современной науки. СПб.: Научный журнал «Globus». 2016. С. 102–107.
  14. Апушкин Д.Ю., Малкова Т.Л. ХАРАКТЕРИСТИКА МЕТАБОЛИЗМА И РАЗРАБОТКА МЕТОДИКИ ОПРЕДЕЛЕНИЯ СИНТЕТИЧЕСКОГО КАННАБИНОИДА AB-PINACA В МОЧЕ ЛАБОРАТОРНЫХ ЖИВОТНЫХ // Здоровье и образование в 21 веке. 2016. Vol. 18. No. 10. С. 113–124.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Apushkin D.Y., Malkova T.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 67428 от 13.10.2016. 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies